

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 May 2001 (17.05.2001)

PCT

(10) International Publication Number
WO 01/35102 A2

(51) International Patent Classification⁷: G01N 33/574,
33/573, A61K 31/7088, 31/713, C12N 15/11, A61K
38/44, 31/44, 47/48, C07K 16/40, C12Q 1/26

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): WANDS, Jack, R.
[US/US]; 210 Varick Road, Waban, MA 02168 (US). DE
LA MONTE, Suzanne, M. [US/US]; 1040 High Hawk
Road, East Greenwich, RI 02818 (US). INCE, Nedim
[TR/US]; Apt. #7, 40 Grove Street, Boston, MA 02114
(US). CARLSON, Rolf, I. [US/US]; 19 Bradford Street,
Boston, MA 02118 (US).

(21) International Application Number: PCT/US00/30738

(22) International Filing Date:
8 November 2000 (08.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/436,184 8 November 1999 (08.11.1999) US

(74) Agent: BEATTIE, Ingrid, A.; Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo PC, One Financial Center, Boston, MA
02111 (US).

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 09/436,184 (CIP)
Filed on 8 November 1999 (08.11.1999)


(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except US*): RHODE
ISLAND HOSPITAL, A LIFESPAN PARTNER
[US/US]; 593 Eddy Street, Providence, RI 02902 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS



(57) Abstract: The invention features a method for diagnosing a malignant neoplasm in a mammal by contacting a bodily fluid from the mammal with an antibody which binds to an human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide and methods of treating malignant neoplasms by inhibiting HAAH. Methods of inhibiting tumor growth by contacting a tumor cell with an HAAH antisense nucleic acid are also included.



patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *Without international search report and to be republished upon receipt of that report.*

DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS

This application claims priority to patent application U.S. Serial No.

5 09/436,184, filed on November 8, 1999.

Statement as to Federally Sponsored Research

This invention was made with U.S. Government support under National Institutes of Health grants CA-35711, AA-02666, AA-02169, and AA11431. The government has certain rights in the invention.

Background of the Invention

10 Primary malignant central nervous system (CNS) neoplasms, particularly glioblastomas, are highly fatal due to their aggressive and widespread infiltration of the brain and resistance to anti-cancer treatments. Although progress has been made in unraveling the pathological mechanisms underlying CNS cancers as well as other cancer
15 types, tumor specific therapeutic approaches and methods of diagnosis have been largely elusive.

Summary of the Invention

The invention features a method for diagnosing a malignant neoplasm in a mammal by contacting a bodily fluid from the mammal with an antibody which binds to
20 an human aspartyl (asparaginy) beta-hydroxylase (HAAH) polypeptide under conditions sufficient to form an antigen-antibody complex and detecting the antigen-antibody complex. Malignant neoplasms detected in this manner include those derived from endodermal tissue, e.g., colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts. Neoplasms of the central nervous system (CNS) such as primary
25 malignant CNS neoplasms of both neuronal and glial cell origin and metastatic CNS neoplasms are also detected. Patient derived tissue samples, e.g., biopsies of solid tumors, as well as bodily fluids such as a CNS-derived bodily fluid, blood, serum, urine, saliva, sputum, lung effusion, and ascites fluid, are contacted with an HAAH-specific antibody.

The assay format is also useful to generate temporal data used for prognosis of malignant disease. A method for prognosis of a malignant neoplasm of a mammal is carried out by (a) contacting a bodily fluid from the mammal with an antibody which binds to an HAAH polypeptide under conditions sufficient to form an antigen-antibody complex and detecting the antigen-antibody complex; (b) quantitating the amount of complex to determine the level of HAAH in the fluid; and (c) comparing the level of HAAH in the fluid with a normal control level of HAAH. An increasing level of HAAH over time indicates a progressive worsening of the disease, and therefore, an adverse prognosis.

10 The invention also includes an antibody which binds to HAAH. The antibody preferably binds to a site in the carboxyterminal catalytic domain of HAAH. Alternatively, the antibody binds to an epitope that is exposed on the surface of the cell. The antibody is a polyclonal antisera or monoclonal antibody. The invention encompasses not only an intact monoclonal antibody, but also an immunologically-active antibody fragment, e. g. , a Fab or (Fab)₂ fragment; an engineered single chain Fv molecule; or a chimeric molecule, e.g., an antibody which contains the binding specificity of one antibody, e.g., of murine origin, and the remaining portions of another antibody, e.g., of human origin. Preferably the antibody is a monoclonal antibody such as FB50, 5C7, 5E9, 19B, 48A, 74A, 78A, 86A, HA238A, HA221, HA 239, HA241, HA329, or 20 HA355. Antibodies which bind to the same epitopes as those monoclonal antibodies are also within the invention.

 An HAAH-specific intrabody is a recombinant single chain HAAH-specific antibody that is expressed inside a target cell, e.g., tumor cell. Such an intrabody binds to endogenous intracellular HAAH and inhibits HAAH enzymatic activity or prevents HAAH from binding to an intracellular ligand. HAAH-specific intrabodies inhibit intracellular signal transduction, and as a result, inhibit growth of tumors which overexpress HAAH.

A kit for diagnosis of a tumor in a mammal contains an HAAH-specific antibody. The diagnostic assay kit is preferentially formulated in a standard two-antibody binding format in which one HAAH-specific antibody captures HAAH in a patient sample and another HAAH-specific antibody is used to detect captured HAAH. For
5 example, the capture antibody is immobilized on a solid phase, e.g., an assay plate, an assay well, a nitrocellulose membrane, a bead, a dipstick, or a component of an elution column. The second antibody, i.e., the detection antibody, is typically tagged with a detectable label such as a colorimetric agent or radioisotope.

Also within the invention is a method of inhibiting tumor growth in a
10 mammal, which is carried out by administering to the mammal a compound which inhibits expression or enzymatic activity of HAAH. Preferably, the compound is substantially pure nucleic acid molecule such as an HAAH antisense DNA, the sequence of which is complementary to a coding sequence of HAAH. Expression of HAAH is inhibited by contacting mammalian cells, e.g., tumor cells, with HAAH antisense DNA or
15 RNA, e.g., a synthetic HAAH antisense oligonucleotide. The sequence of the antisense is complementary to a coding or noncoding region of a HAAH gene. For example, the sequence is complementary to a nucleotide sequence in the 5' untranslated region of a HAAH gene. Examples of HAAH antisense oligonucleotides which inhibit HAAH expression in mammalian cells include oligonucleotides containing SEQ ID NO:10, 11,
20 or 12. An HAAH antisense nucleic acid is introduced into glioblastoma cells or other tumor cells which overexpress HAAH. Binding of the antisense nucleic acid to an HAAH transcript in the target cell results in a reduction in HAAH production by the cell. By the term "antisense nucleic acid" is meant a nucleic acid (RNA or DNA) which is complementary to a portion of an mRNA, and which hybridizes to and prevents
25 translation of the mRNA. Preferably, the antisense DNA is complementary to the 5' regulatory sequence or the 5' portion of the coding sequence of HAAH mRNA (e.g., a sequence encoding a signal peptide or a sequence within exon 1 of the HAAH gene).

Standard techniques of introducing antisense DNA into the cell may be used, including those in which antisense DNA is a template from which an antisense RNA is transcribed.

The method is to treat tumors in which expression of HAAH is upregulated, e.g., as a result of malignant transformation of the cells. The length of the oligonucleotide is at least 10 nucleotides and may be as long as the naturally-occurring HAAH transcript. Preferably, the length is between 10 and 50 nucleotides, inclusive. More preferably, the length is between 10 and 20 nucleotides, inclusive.

By "substantially pure DNA or RNA" is meant that the nucleic acid is free of the genes which, in the naturally-occurring genome of the organism from which the DNA of the invention is derived, flank a HAAH gene. The term therefore includes, for example, a recombinant nucleic acid which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a procaryote or eucaryote at a site other than its natural site; or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant nucleic acid which is part of a hybrid gene encoding additional polypeptide sequence such as a nucleic acid encoding an chimeric polypeptide, e.g., one encoding an antibody fragment linked to a cytotoxic polypeptide. Alternatively, HAAH expression is inhibited by administering a ribozyme or a compound which inhibits binding of Fos or Jun to an HAAH promoter sequence.

Compounds, which inhibit an enzymatic activity of HAAH, are useful to inhibit tumor growth in a mammal. By enzymatic activity of HAAH is meant hydroxylation of an epidermal growth factor (EGF)-like domain of a polypeptide. For example an EGF-like domain has the consensus sequence CX₇CX₄CX₁₀CXCX₈C (SEQ ID NO:1). HAAH hydroxylase activity is inhibited intracellularly. For example, a dominant negative mutant of HAAH (or a nucleic acid encoding such a mutant) is administered. The dominant negative HAAH mutant contains a mutation which changes

a ferrous iron binding site from histidine of a naturally-occurring HAAH sequence to a non-iron-binding amino acid, thereby abolishing the hydroxylase activity of HAAH. The histidine to be mutated, e.g., deleted or substituted, is located in the carboxyterminal catalytic domain of HAAH. For example, the mutation is located between amino acids 5 650-700 (such as the His motif, underlined sequence of SEQ ID NO:2) the native HAAH sequence. For example, the mutation is at residues 671, 675, 679, or 690 of SEQ ID NO:2. An HAAH-specific intrabody is also useful to bind to HAAH and inhibit intracellular HAAH enzymatic activity, e.g., by binding to an epitope in the catalytic domain of HAAH. Other compounds such as L-mimosine or hydroxypyridone are 10 administered directly into a tumor site or systemically to inhibit HAAH hydroxylase activity.

Table 1: Amino acid sequence of HAAH

	MAQRKNAKSS	GNSSSSGSGS	GSTSAGSSSP	GARRETKHGG	HKNGRKGGLS	GTSFFTWFMV	61
	IALLGWTSV	AVVWFDLVDY	EEVLGKLGII	DADGDGDFDV	DDAKVLLGLK	ERSTSEPAVP	121
15	PEEAEPHTEP	EEQVPVEAEP	QNIIDEAKEQ	IQSLLHEMVH	AEHVEGEDLQ	QEDGPTGEPQ	181
	QEDDEFLMAT	DVDDRFETLE	PEVSHEETEH	SYHVEETVSQ	DCNQDMEMM	SEQENPDSSE	241
	PVVEDERLHH	DTDDVTYQVY	EEQAVYEPL	NEGIEITEVT	APPEDNPVED	SQVIVEEVS	301
	FPVEEQQEV	PETNRKTDDP	EQKAKVKKKK	PKLLNKFDKT	IKAELDAEK	LRKRGKIEEA	361
	VNAFKELVRK	YPQSPRARYG	KAQCEDDLAE	KRRSNEVLRG	AIETYQEVAS	LPDVPADLLK	421
20	LSLKRRSDRQ	QFLGHMRGSL	LTQLRLVQLF	PNDTSLKNDL	GVGYLLIGDN	DNAKKVYEEV	481
	LSVTPNDGFA	KVHYGFILKA	QNKIAESIPY	LKEGIESGDP	GTDDGRFYFH	LGDAMQRVGN	541
	KEAYKWYELG	HKRGHFASVW	QRLYNVNGL	KAQPWWTPKE	TGYTELVKSL	ERNWKLIRDE	601
	GLAVMDKAKG	LFLPEDENLR	EKGDWSQFTL	WQQGRRNENA	CKGAPKTCTL	LEKFPETTGC	661
	RRGQIKYSIM	HPGTHVWPHT	GPTNCRLRMH	LGLVIPKEGC	KIRCANETRT	WEEGKVLIFD	721
25	DSFEHEVWQD	ASSFRLIFIV	DVWHPELTPO	QRRSLPAI	(SEQ ID NO:2; GENBANK Accession No. S83325; His motif is underlined; conserved sequences within the catalytic domain are designated by bold type)		

For example, a compound which inhibits HAAH hydroxylation is a polypeptide that binds a HAAH ligand but does not transduce an intracellular signal or an 30 polypeptide which contains a mutation in the catalytic site of HAAH. Such a polypeptide contains an amino acid sequence that is at least 50% identical to a naturally-occurring HAAH amino acid sequence or a fragment thereof and which has the ability to inhibit HAAH hydroxylation of substrates containing an EGF-like repeat sequence. More preferably, the polypeptide contains an amino acid sequence that is at least 75%, more

preferably at least 85%, more preferably at least 95% identical to SEQ ID NO:2.

A substantially pure HAAH polypeptide or HAAH-derived polypeptide such as a mutated HAAH polypeptide is preferably obtained by expression of a recombinant nucleic acid encoding the polypeptide or by chemically synthesizing the protein.

- 5 A polypeptide or protein is substantially pure when it is separated from those contaminants which accompany it in its natural state (proteins and other naturally-occurring organic molecules). Typically, the polypeptide is substantially pure when it constitutes at least 60%, by weight, of the protein in the preparation. Preferably, the protein in the preparation is at least 75%, more preferably at least 90%, and most
- 10 preferably at least 99%, by weight, HAAH. Purity is measured by any appropriate method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis. Accordingly, substantially pure polypeptides include recombinant polypeptides derived from a eucaryote but produced in *E. coli* or another procaryote, or in a eucaryote other than that from which the polypeptide was originally derived.
- 15 Nucleic acid molecules which encode such HAAH or HAAH-derived polypeptides are also within the invention.

Table 2: HAAH cDNA sequence

	cggaccgtgc	aatggcccag	cgtaagaatg	ccaagagcag	cggcaacagc	agcagcagcg	61
	gctccggcag	cggtagcacg	agtgcgggca	gcagcagccc	cggggcccgg	agagagacaa	121
20	agcatggagg	acacaagaat	gggaggaaag	gcggaactctc	gggaacttca	ttcttcacgt	181
	ggtttatggt	gattgcattg	ctgggcgtct	ggacatctgt	agctgtcggt	tggtttgatc	241
	ttgttgacta	tgaggaagtt	ctaggaaaac	taggaatcta	tgatgctgat	ggtgatggag	301
	atthttgatgt	ggatgatgcc	aaagttttat	taggacttaa	agagagatct	acttcagagc	361
	cagcagtccc	gccagaagag	gctgagccac	acactgagcc	cgaggagcag	gttcctgtgg	421
25	aggcagaacc	ccagaatatc	gaagatgaag	caaaaagaaca	aattcagtcc	cttctccatg	481
	aaatggtaca	cgcagaacat	gttgagggag	aagacttgca	acaagaagat	ggaccacacg	541
	gagaaccaca	acaagaggat	gatgagtttc	ttatggcgac	tgatgtagat	gatagatttg	601
	agaccctgga	acctgaagta	tctcatgaag	aaaccgagca	tagttaccac	gtggaagaga	661
	cagtttcaca	agactgtaat	caggatatgg	aagagatgat	gtctgagcag	gaaaatccag	721
30	attccagtga	accagtagta	gaagatgaaa	gattgcacca	tgatacagat	gatgtaacat	781
	accaagtcta	tgaggaacaa	gcagtatatg	aacctctaga	aaatgaaggg	atagaaatca	841
	cagaagtaac	tgctccccct	gaggataatc	ctgtagaaga	ttcacaggta	attgtagaag	901
	aagtaagcat	ttttcctgtg	gaagaacagc	aggaagtacc	accagaaaca	aatagaaaaa	961
	cagatgatcc	agaacaaaaa	gcaaaagtta	agaaaaagaa	gcctaaactt	ttaaataaat	1021
35	ttgataagac	tattaaagct	gaacttgatg	ctgcagaaaa	actccgtaaa	aggggaaaaa	1081
	ttgaggaagc	agtgaatgca	tttaagaac	tagtacgcaa	ataccctcag	agtcacacgag	1141
	caagatatgg	gaaggcgag	tgtgaggatg	atttggtctga	gaagaggaga	agtaatgagg	1201

tgctacgtgg agccatcgag acctaccaag aggtggccag cctacctgat gtccttgcag 1261
 acctgctgaa gctgagtttg aagcgtcgt cagacaggca acaatttcta ggatcatatga 1321
 gaggttccct gcttaccctg cagagattag ttcaactatt tcccaatgat acttccttaa 1381
 aaaatgacct tggcgtggga tacctcttga taggagataa tgacaatgca aagaaagtgt 1441
 5 atgaagaggt gctgagtgat acacctaagt atggctttgc taaagtccat tatggcttca 1501
 tcctgaaggc acagaacaaa attgctgaga gcatcccata tttaaaggaa ggaatagaat 1561
 ccggagatcc tggcactgat gatgggagat tttatttcca cctgggggat gccatgcaga 1621
 ggggttgggaa caaagaggca tataagtggg atgagcttgg gcacaagaga ggacactttg 1681
 catctgtctg gcaacgctca ctctacaatg tgaatggact gaaagcacag ccttggtgga 1741
 10 ccccaaaaga aacgggctac acagagttag taaagtcttt agaaagaaac tggaggttaa 1801
 tccgagatga aggccttgca gtgatggata aagccaaagg tctcttctct cctgaggatg 1861
 aaaacctgag ggaagaaagg gactggagcc agttcacgct gtggcagcaa ggaagaagaa 1921
 atgaaaatgc ctgcaagaga gctcctaata cctgtacct actagaaaag tccccgaga 1981
 caacaggatg cagaagagga cagatcaaat attccatcat gcaccccggt actcacgtgt 2041
 15 ggccgcacac agggcccaaca aactgcaggg tccgaatgca cctgggcttg gtgattccca 2101
 aggaaggctg caagattcga tgtgccaaag agaccaggac ctgggaggaa ggcaagggtgc 2161
 tcattcttga tgactccttt gagcacgagg tatggcagga tgctcatct ttcgggtcga 2221
 tattcatcgt ggaatgtgg catccggaac tgacaccaca gcagagacgc agccttccag 2281
 caatttagca tgaattcatg caagcttggg aaactctgga gaga
 20 (SEQ ID NO:3 ; GENBANK Accession No. S83325; codon encoding initiating
 methionine is underlined).

Methods of inhibiting tumor growth also include administering a compound
 which inhibits HAAH hydroxylation of a NOTCH polypeptide. For example, the
 compound inhibits hydroxylation of an EGF-like cysteine-rich repeat sequence in a
 25 NOTCH polypeptide, e.g., one containing the consensus sequence
 CDXXXCXXKXGNGXCDXXCNNAACXXDGXDC (SEQ ID NO:4). Polypeptides
 containing an EGF-like cysteine-rich repeat sequence are administered to block
 hydroxylation of endogenous NOTCH.

Growth of a tumor which overexpresses HAAH is also inhibited by
 30 administering a compound which inhibits signal transduction through the insulin receptor
 substrate (IRS) signal transduction pathway. Preferably the compound inhibits IRS
 phosphorylation. For example, the compound is a peptide or non-peptide compound
 which binds to and inhibits phosphorylation at residues 46, 465, 551, 612, 632, 662, 732,
 941, 989, or 1012 of SEQ ID NO:5. Compounds include polypeptides such those which
 35 block an IRS phosphorylation site such as a Glu/Tyr site. Antibodies such as those which
 bind to a carboxyterminal domain of IRS containing a phosphorylation site block IRS
 phosphorylation, and as a consequence, signal transduction along the pathway. Inhibition

of IRS phosphorylation in turn leads to inhibition of cell proliferation. Other compounds which inhibit IRS phosphorylation include vitamin D analogue EB1089 and Wortmannin.

HAAH-overproducing tumor cells were shown to express HAAH both intracellularly and on the surface of the tumor cell. Accordingly, a method of killing a tumor cell is carried out by contacting such a tumor cell with a cytotoxic agent linked to an HAAH-specific antibody. The HAAH-specific antibody (antibody fragment, or ligand which binds to extracellular HAAH) directs the chimeric polypeptide to the surface of the tumor cell allowing the cytotoxic agent to damage or kill the tumor cell to which the antibody is bound. The monoclonal antibody binds to an epitope of HAAH such as an epitope exposed on the surface of the cell or in the catalytic site of HAAH. The cytotoxic composition preferentially kills tumor cells compared to non-tumor cell.

Screening methods to identify anti-tumor agents which inhibit the growth of tumors which overexpress HAAH are also within the invention. A screening method used to determine whether a candidate compound inhibits HAAH enzymatic activity includes the following steps: (a) providing a HAAH polypeptide, e.g., a polypeptide which contains the carboxyterminal catalytic site of HAAH; (b) providing a polypeptide comprising an EGF-like domain; (c) contacting the HAAH polypeptide or the EGF-like polypeptide with the candidate compound; and (d) determining hydroxylation of the EGF-like polypeptide of step (b). A decrease in hydroxylation in the presence of the candidate compound compared to that in the absence of said compound indicates that the compound inhibits HAAH hydroxylation of EGF-like domains in proteins such as NOTCH.

Anti-tumor agents which inhibit HAAH activation of NOTCH are identified by (a) providing a cell expressing HAAH; (b) contacting the cell with a candidate compound; and (c) measuring translocation of activated NOTCH to the nucleus of said cell. Translocation is measured by using a reagent such as an antibody which binds to a 110 kDa activation fragment of NOTCH. A decrease in translocation in the presence of

the candidate compound compared to that in the absence of the compound indicates that the compound inhibits HAAH activation of NOTCH, thereby inhibiting NOTCH-mediated signal transduction and proliferation of HAAH-overexpressing tumor cells.

Nucleotide and amino acid comparisons described herein were carried out using the Lasergene software package (DNASTAR, Inc., Madison, WI). The MegAlign module used was the Clustal V method (Higgins et al., 1989, CABIOS 5(2):151-153). The parameter used were gap penalty 10, gap length penalty 10.

Hybridization is carried out using standard techniques, such as those described in Ausubel *et al.* (*Current Protocols in Molecular Biology*, John Wiley & Sons, 1989). "High stringency" refers to nucleic acid hybridization and wash conditions characterized by high temperature and low salt concentration, *e.g.*, wash conditions of 65°C at a salt concentration of 0.1 X SSC. "Low" to "moderate" stringency refers to DNA hybridization and wash conditions characterized by low temperature and high salt concentration, *e.g.*, wash conditions of less than 60°C at a salt concentration of 1.0 X SSC. For example, high stringency conditions include hybridization at 42°C in the presence of 50% formamide; a first wash at 65°C in the presence of 2 X SSC and 1% SDS; followed by a second wash at 65°C in the presence of 0.1% x SSC. Lower stringency conditions suitable for detecting DNA sequences having about 50% sequence identity to an HAAH gene sequence are detected by, for example, hybridization at about 42°C in the absence of formamide; a first wash at 42°C, 6 X SSC, and 1% SDS; and a second wash at 50°C, 6 X SSC, and 1% SDS.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

Brief Description of the Drawings

Fig. 1 is a bar graph showing colony formation induced by transient transfection of NIH-3T3 cells with various aspartyl (asparaginyl) beta-hydroxylase (AAH) cDNAs. Colony formation was induced by transient transfection with 10 μ g DNA.

5 In contrast, the mutant murine AAH construct without enzymatic activity has no transforming activity. The data is presented as mean number of transformed foci \pm SEM.

Fig. 2 is a bar graph showing the results of a densitometric analysis of a Western blot assay of proteins produced by various murine AAH stably transfected cell clones. In clones 7 and 18, there was a modest increase in HAAH gene expression, while
10 the overexpression was to a lesser degree in clone 16.

Figs. 3A-B are bar graphs showing colony formation in soft agar exhibited by HAAH stably transfected clones compared to HAAH enzymatic activity. Fig. 3A shows a measurement of murine AAH enzymatic activity in clones 7, 16 and 18, and Fig. 3B shows colony formation exhibited by clones 7, 16 and 18. Data is presented as mean
15 number of colonies 10 days after plating \pm SEM. All three clones with modest increases in HAAH enzymatic activity, that correlated with protein expression, exhibited anchorage independent growth.

Fig. 4 is a bar graph showing tumor formation in nude mice injected with transfected clones overexpressing murine AAH. Tumor growth was assessed after
20 30 days. Mean tumor weight observed in mice injected with clones 7, 16 and 18 as compared to mock DNA transfected clone. All animals, which were injected with clones overexpressing HAAH, developed tumors.

Figs. 5A-D are bar graphs showing increased AAH expression in PNET2 (Fig. 5A, 5C) and SH-Sy5y (Fig. 5B) cells treated with retinoic acid (Figs. 5A, 5B) or phorbol ester myristate (PMA; Fig. 5C) to induce neurite outgrowth as occurs during tumor cell
25 invasion. The cells were treated with 10 μ M retinoic acid or 100 nM PMA for 0, 1, 2, 3, 4, or 7 days. Cell lysates were analyzed by Western blot analysis using an HAAH-specific

monoclonal antibody to detect the 85 kDa AAH protein. The levels of immunoreactivity were measured by volume densitometry (arbitrary units). The graphs indicate the mean \pm S.D. of results obtained from three separate experiments. In Fig. 5D, PNET2 cells were treated for 24 hours with sub-lethal concentrations of H₂O₂ to induce neurite retraction.

- 5 Viability of greater than 90% of the cells was demonstrated by Trypan blue dye exclusion. Similar results were obtained for SH-Sy5y cells.

Fig. 6 is a bar graph showing the effects of AAH over-expression on the levels of anti-apoptosis (Bcl-2), cell cycle-mitotic inhibitor (p16 and p21/Waf1), and proliferation (proliferating cell nuclear antigen; PCNA) molecules. PNET2 neuronal
10 cells were stably transfected with the full-length human cDNA encoding AAH (pHAAH) or empty vector (pcDNA). AAH gene expression was under control of a CMV promoter. Western blot analysis was performed with cell lysates prepared from cultures that were 70 to 80 percent confluent. Protein loading was equivalent in each lane. Replicate blots were probed with the different antibodies. Bar graphs depict the mean S.D.'s of protein
15 expression levels measured in three experiments. All differences are statistically significant by Student T-test analysis ($P < 0.01$ - $P < 0.001$).

Fig. 7 is a diagram of showing the components of the IRS-1 signal transduction pathway.

Fig. 8 is a line graph showing growth curves generated in cells expressing the
20 antisense HAAH compared to controls expressing GFP.

Fig. 9 is a diagram of the functional domains of the hIRS-1 protein and structural organization of the point mutants. All mutant and "wild type" hIRS-1 proteins construct contain a FLAG (F) epitope (DYKDDDDK; SEQ ID NO:7) at the C-terminus. PH and PTB indicate pleckstrin homology and phosphotyrosine binding, regions,
25 respectively.

Fig. 10 is a diagram showing AAH cDNA and the location at which antisense oligonucleotides bind. The locations shown are relative to the AUG start site of the AAH

cDNA.

Fig. 11 is a photograph of an electrophoretic gel showing inhibition of AAH gene expression by antisense oligonucleotide DNA molecules.

Fig. 12 is a line graph showing AAH antisense oligonucleotide binding in
5 neuroblastoma cells.

Fig. 13 is a bar graph showing inhibition of AAH gene expression as a result of AAH antisense oligonucleotide delivery into neuroblastoma cells.

Fig. 14A is a photograph of a Western blot assay expression of NOTCH proteins.

10 Fig. 14B is a photograph of an electrophoretic gel showing Hes-1 gene expression as measured by reverse transcriptase - polymerase chain reaction (RT-PCR).

Fig. 14C is a photograph of a Western blot assay showing expression of NOTCH-1 and Jagged-1 under conditions in which IRS-1 signalling is reduced.

Detailed Description

15 HAAH is a protein belonging to the (alpha-ketoglutarate dependent dioxygenase family of prolyl and lysyl hydroxylases which play a key role in collagen biosynthesis. This molecule hydroxylates aspartic acid or asparagine residues in EGF-like domains of several proteins in the presence of ferrous iron. These EGF-like domains contain conserved motifs, that form repetitive sequences in proteins such as clotting
20 factors, extracellular matrix proteins, LDL receptor, NOTCH homologues, or NOTCH ligand homologues.

The alpha-ketoglutarate-dependent dioxygenase aspartyl (asparaginyl) beta-hydroxylase (AAH) specifically hydroxylates one aspartic or asparagine residue in EGF-like domains of various proteins. The 4.3-kb cDNA encoding the human AspH
25 (hAspH) hybridizes with 2.6 kb and 4.3 kb transcripts in transformed cells, and the deduced amino acid sequence of the larger transcript encodes an protein of about 85 kDa. Both *in vitro* transcription and translation and Western blot analysis also demonstrate a

56-kDa protein that may result from posttranslational cleavage of the catalytic C-terminus.

A physiological function of AAH is the post-translational beta-hydroxylation of aspartic acid in vitamin K-dependent coagulation proteins. However, the abundant
5 expression of AAH in several malignant neoplasms, and low levels of AAH in many normal cells indicate a role for this enzyme in malignancy. The AAH gene is also highly expressed in cytotrophoblasts, but not syncytiotrophoblasts of the placenta. Cytotrophoblasts are invasive cells that mediate placental implantation. The increased levels of AAH expression in human cholangiocarcinomas, hepatocellular carcinomas,
10 colon cancers, and breast carcinomas were primarily associated with invasive or metastatic lesions. Moreover, overexpression of AAH does not strictly reflect increased DNA synthesis and cellular proliferation since high levels of AAH immunoreactivity were observed in 100 percent of cholangiocarcinomas, but not in human or experimental disease processes associated with regeneration or nonneoplastic proliferation of bile
15 ducts. AAH overexpression and attendant high levels of beta hydroxylase activity lead to invasive growth of transformed neoplastic cells. Detection of an increase in HAAH expression is useful for early and reliable diagnosis of the cancer types which have now been characterized as overexpressing this gene product.

Diagnosis of malignant tumors

20 HAAH is overexpressed in many tumors of endodermal origin and in at least 95% of CNS tumors compared to normal noncancerous cells. An increase in HAAH gene product in a patient-derived tissue sample (e.g., solid tissue or bodily fluid) is carried out using standard methods, e.g., by Western blot assays or a quantitative assay such as ELISA. For example, a standard competitive ELISA format using an HAAH-
25 specific antibody is used to quantify patient HAAH levels. Alternatively, a sandwich ELISA using a first antibody as the capture antibody and a second HAAH-specific antibody as a detection antibody is used.

Methods of detecting HAAH include contacting a component of a bodily fluid with an HAAH-specific antibody bound to solid matrix, e.g., microtiter plate, bead, dipstick. For example, the solid matrix is dipped into a patient-derived sample of a bodily fluid, washed, and the solid matrix is contacted with a reagent to detect the
5 presence of immune complexes present on the solid matrix.

Proteins in a test sample are immobilized on (e.g., bound to) a solid matrix. Methods and means for covalently or noncovalently binding proteins to solid matrices are known in the art. The nature of the solid surface may vary depending upon the assay format. For assays carried out in microtiter wells, the solid surface is the wall of the
10 microtiter well or cup. For assays using beads, the solid surface is the surface of the bead. In assays using a dipstick (i.e., a solid body made from a porous or fibrous material such as fabric or paper) the surface is the surface of the material from which the dipstick is made. Examples of useful solid supports include nitrocellulose (e.g., in membrane or microtiter well form), polyvinyl chloride (e.g., in sheets or microtiter wells), polystyrene
15 latex (e.g., in beads or microtiter plates, polyvinylidene fluoride (known as IMMULON™), diazotized paper, nylon membranes, activated beads, and Protein A beads. The solid support containing the antibody is typically washed after contacting it with the test sample, and prior to detection of bound immune complexes. Incubation of the antibody with the test sample is followed by detection of immune complexes by a
20 detectable label. For example, the label is enzymatic, fluorescent, chemiluminescent, radioactive, or a dye. Assays which amplify the signals from the immune complex are also known in the art, e.g., assays which utilize biotin and avidin.

An HAAH-detection reagent, e.g., an antibody, is packaged in the form of a kit, which contains one or more HAAH-specific antibodies, control formulations
25 (positive and/or negative), and/or a detectable label. The assay may be in the form of a standard two-antibody sandwich assay format known in the art.

Production of HAAH-specific antibodies

Anti-HAAH antibodies were obtained by techniques well known in the art. Such antibodies are polyclonal or monoclonal. Polyclonal antibodies were obtained using standard methods, e.g., by the methods described in Ghose et al., Methods in Enzymology, Vol. 93, 326-327, 1983. An HAAH polypeptide, or an antigenic fragment thereof, was used as the immunogen to stimulate the production of polyclonal antibodies in the antisera of rabbits, goats, sheep, or rodents. Antigenic polypeptides for production of both polyclonal and monoclonal antibodies useful as immunogens include polypeptides which contain an HAAH catalytic domain. For example, the immunogenic polypeptide is the full-length mature HAAH protein or an HAAH fragment containing the carboxyterminal catalytic domain e.g., an HAAH polypeptide containing the His motif of SEQ ID NO:2.

Antibodies which bind to the same epitopes as those antibodies disclosed herein are identified using standard methods, e.g., competitive binding assays, known in the art.

Monoclonal antibodies were obtained by standard techniques. Ten μ g of purified recombinant HAAH polypeptide was administered to mice intraperitoneally in complete Freund's adjuvant, followed by a single boost intravenously (into the tail vein) 3-5 months after the initial inoculation. Antibody-producing hybridomas were made using standard methods. To identify those hybridomas producing antibodies that were highly specific for an HAAH polypeptide, hybridomas were screened using the same polypeptide immunogen used to immunize. Those antibodies which were identified as having HAAH-binding activity are also screened for the ability to inhibit HAAH catalytic activity using the enzymatic assays described below. Preferably, the antibody has a binding affinity of at least about 10^8 liters/mole and more preferably, an affinity of at least about 10^9 liters/mole.

Monoclonal antibodies are humanized by methods known in the art, e.g., MAbs with a desired binding specificity can be commercially humanized (Scotgene,

Scotland; Oxford Molecular, Palo Alto, CA).

HAAH-specific intrabodies are produced as follows. Following identification of a hybridoma producing a suitable monoclonal antibody, DNA encoding the antibody is cloned. DNA encoding a single chain HAAH-specific antibody in which heavy and light chain variable domains are separated by a flexible linker peptide is cloned into an expression vector using known methods (e.g., Marasco et al., 1993, Proc. Natl. Acad. Sci. USA 90:7889-7893 and Marasco et al., 1997, Gene Therapy 4:11-15). Such constructs are introduced into cells, e.g., using standard gene delivery techniques for intracellular production of the antibodies. Intracellular antibodies, i.e., intrabodies, are used to inhibit signal transduction by HAAH. Intrabodies which bind to a carboxyterminal catalytic domain of HAAH inhibit the ability of HAAH to hydroxylate EGF-like target sequences.

Methods of linking HAAH-specific antibodies (or fragments thereof) which bind to cell surface exposed epitopes of HAAH on the surface of a tumor cell are linked to known cytotoxic agents, e.g, ricin or diptheria toxin, using known methods.

Methods of treating malignant tumors

Patients with tumors characterized as overexpressing HAAH as such tumors of endodermal origin or CNS tumors are treated by administering HAAH antisense nucleic acids.

Antisense therapy is used to inhibit expression of HAAH in patients suffering from hepatocellular carcinomas, cholangiocarcinomas, glioblastomas and neuroblastomas. For example, an HAAH antisense strand (either RNA or DNA) is directly introduced into the cells in a form that is capable of binding to the mRNA transcripts. Alternatively, a vector containing a sequence which, which once within the target cells, is transcribed into the appropriate antisense mRNA, may be administered. Antisense nucleic acids which hybridize to target mRNA decrease or inhibit production of the polypeptide product encoded by a gene by associating with the normally single-

stranded mRNA transcript, thereby interfering with translation and thus, expression of the protein. For example, DNA containing a promoter, e.g., a tissue-specific or tumor specific promoter, is operably linked to a DNA sequence (an antisense template), which is transcribed into an antisense RNA. By "operably linked" is meant that a coding
5 sequence and a regulatory sequence(s) (i.e., a promoter) are connected in such a way as to permit gene expression when the appropriate molecules (e.g., transcriptional activator proteins) are bound to the regulatory sequence(s).

Oligonucleotides complementary to various portions of HAAH mRNA were tested *in vitro* for their ability to decrease production of HAAH in tumor cells (e.g., using
10 the FOCUS hepatocellular carcinoma (HCC) cell line) according to standard methods. A reduction in HAAH gene product in cells contacted with the candidate antisense composition compared to cells cultured in the absence of the candidate composition is detected using HAAH-specific antibodies or other detection strategies. Sequences which decrease production of HAAH in *in vitro* cell-based or cell-free assays are then be tested
15 *in vivo* in rats or mice to confirm decreased HAAH production in animals with malignant neoplasms.

Antisense therapy is carried out by administering to a patient an antisense nucleic acid by standard vectors and/or gene delivery systems. Suitable gene delivery systems may include liposomes, receptor-mediated delivery systems, naked DNA, and
20 viral vectors such as herpes viruses, retroviruses, adenoviruses and adeno-associated viruses, among others. A reduction in HAAH production results in a decrease in signal transduction via the IRS signal transduction pathway. A therapeutic nucleic acid composition is formulated in a pharmaceutically acceptable carrier. The therapeutic composition may also include a gene delivery system as described above.

25 Pharmaceutically acceptable carriers are biologically compatible vehicles which are suitable for administration to an animal: e.g., physiological saline. A therapeutically effective amount of a compound is an amount which is capable of producing a medically

desirable result such as reduced production of an HAAH gene product or a reduction in tumor growth in a treated animal.

Parenteral administration, such as intravenous, subcutaneous, intramuscular, and intraperitoneal delivery routes, may be used to deliver nucleic acids or HAAH-inhibitory peptides or non-peptide compounds. For treatment of CNS tumors, direct infusion into cerebrospinal fluid is useful. The blood-brain barrier may be compromised in cancer patients, allowing systemically administered drugs to pass through the barrier into the CNS. Liposome formulations of therapeutic compounds may also facilitate passage across the blood-brain barrier.

Dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular nucleic acid to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. Dosage for intravenous administration of nucleic acids is from approximately 10^6 to 10^{22} copies of the nucleic acid molecule.

Ribozyme therapy is also be used to inhibit HAAH gene expression in cancer patients. Ribozymes bind to specific mRNA and then cut it at a predetermined cleavage point, thereby destroying the transcript. These RNA molecules are used to inhibit expression of the HAAH gene according to methods known in the art (Sullivan et al., 1994, J. Invest. Derm. 103:85S-89S; Czubayko et al., 1994, J. Biol. Chem. 269:21358-21363; Mahieu et al, 1994, Blood 84:3758-65; Kobayashi et al. 1994, Cancer Res. 54:1271-1275).

Activation of NOTCH signaling

NOTCH signalling is activated in cells highly expressing AAH. Fig. 14A. shows the presence of a 110 kDa NOTCH fragment as revealed by using Western blot. Overexpression of enzymatically active AAH is shown by a display of the 100 kDa cleaved, active NOTCH-1 (Lane 1, Mock DNA transfected clone; Lane 2, clones 7; and Lane 3, clone18). In contrast, NOTCH-2 was not activated. There was enhanced

expression of the full length Jagged ligand in clones expressing AAH as compared to the mock DNA transfected clone. Tubulin was used as internal control for protein loading.

Expression of the Hes-1, a known downstream effector gene, is activated by NOTCH signaling (Fig. 14B). Only AAH-expressing clones activate Notch expression as
 5 a transcription factor and subsequently unregulates Hes-1 gene expression as revealed by competitive RT-PCR. Lower panel is an RT-PCR product of GAPDH that served as internal control. Fig. 14C shows expression of human NOTCH-1 (hNOTCH-1) and Jagged-1 where IRS-1 signaling is reduced by a dominant negative mutant (DhIRS-1). Such cells demonstrate downregulation AAH expression and demonstrate a parallel
 10 decrease in NOTCH-1 and Jagged levels by Western blot analysis. Tubulin was used as an internal control for protein loading.

Methods of identifying compounds that inhibit HAAH enzymatic activity

Aspartyl (asparaginyl) beta-hydroxylase (AAH) activity is measured *in vitro* or *in vivo*. For example, HAAH catalyzes posttranslational
 15 modification of β carbon of aspartyl and asparaginyl residues of EGF-like polypeptide domains. An assay to identify compounds which inhibit hydroxylase activity is carried out by comparing the level of hydroxylation in an enzymatic reaction in which the candidate compound is present compared to a parallel reaction in the absence of the compound (or a predetermined control value). Standard hydroxylase assays carried out in
 20 a testtube are known in the art, e.g., Lavaissiere et al., 1996, J. Clin. Invest. 98:1313-1323; Jia et al., 1992, J. Biol. Chem. 267:14322-14327; Wang et al., 1991, J. Biol. Chem. 266:14004-14010; or Gronke et al., 1990, J. Biol. Chem. 265:8558-8565. Hydroxylase activity is also measured using carbon dioxide ($^{14}\text{CO}_2$ capture assay) in a 96-well microtiter plate format (Zhang et al., 1999, Anal. Biochem. 271:137-142. These assays
 25 are readily automated and suitable for high throughput screening of candidate compounds to identify those with hydroxylase inhibitory activity.

Candidate compound which inhibit HAAH activation of NOTCH are

identified by detecting a reduction in activated NOTCH in a cell which expresses or overexpresses HAAH, e.g., FOCUS HCC cells. The cells are cultured in the presence of a candidate compound. Parallel cultures are incubated in the absence of the candidate compound. To evaluate whether the compound inhibits HAAH activation of NOTCH,

5 translocation of activated NOTCH to the nucleus of the cell is measured. Translocation is measured by detecting a 110 kDa activation fragment of NOTCH in the nucleus of the cell. The activation fragment is cleaved from the large (approximately 300 kDa) transmembrane NOTCH protein upon activation. Methods of measuring NOTCH translocation are known, e.g, those described by Song et al., 1999, Proc. Natl. Acad. Sci

10 U.S.A. 96:6959-6963 or Capobianco et al., 1997, Mol. Cell Biol. 17:6265-6273. A decrease in translocation in the presence of the candidate compound compared to that in the absence of the compound indicates that the compound inhibits HAAH activation of NOTCH, thereby inhibiting NOTCH-mediated signal transduction and proliferation of HAAH-overexpressing tumor cells.

15 Methods of screening for compounds which inhibit phosphorylation of IRS are carried out by incubating IRS-expressing cells in the presence and absence of a candidate compound and evaluating the level of IRS phosphorylation in the cells. A decrease in phosphorylation in cells cultured in the presence of the compound compared to in the absence of the compound indicates that the compound inhibits IRS-1

20 phosphorylation, and as a result, growth of HAAH-overexpressing tumors. Alternatively, such compounds are identified in an *in vitro* phosphorylation assay known in the art, e.g., one which measured phosphorylation of a synthetic substrate such as poly (Glu/Tyr).

Example 1: Increased expression of HAAH is associated with malignant transformation

HAAH is a highly conserved enzyme that hydroxylates EGF-like domains in transformation associated proteins. The HAAH gene is overexpressed in many cancer types including human hepatocellular carcinomas and cholangiocarcinomas. HAAH gene
5 expression was found to be undetectable during bile duct proliferation in both human disease and rat models compared to cholangiocarcinoma. Overexpression of HAAH in NIH-3T3 cells was associated with generation of a malignant phenotype, and enzymatic activity was found to be required for cellular transformation. The data described below indicate that overexpression of HAAH is linked to cellular transformation of biliary
10 epithelial cells.

To identify molecules that are specifically overexpressed in transformed malignant cells of human hepatocyte origin, the FOCUS hepatocellular carcinoma (HCC) cell line was used as an immunogen to generate monoclonal antibodies (mAb) that specifically or preferentially recognize proteins associated with the malignant phenotype.
15 A lambda GT11 cDNA expression library derived from HepG2 HCC cells was screened, and a HAAH-specific mAb produced against the FOCUS cell line was found to recognize an epitope on a protein encoded by an HAAH cDNA. The HAAH enzyme was found to be upregulated in several different human transformed cell lines and tumor tissues compared to adjacent human tissue counterparts. The overexpressed HAAH enzyme in
20 different human malignant tissues was found to be catalytically active.

HAAH gene expression was examined in proliferating bile ducts and in NIH 3T3 cells. Its role in the generation of the malignant phenotype was measured by the formation of transformed foci, growth in soft agar as an index of anchorage independent growth and tumor formation in nude mice. The role of enzymatic activity in the
25 induction of transformed phenotype was measured by using a cDNA construct with a mutation in the catalytic site that abolished hydroxylase activity. The results indicated that an increase in expression of HAAH gene is associated with malignant transformation

of bile ducts.

The following materials and methods were used to generate the data described below.

Antibodies

5 The FB50 monoclonal antibody was generated by cellular immunization of Balb/C mice with FOCUS HCC cells. A monoclonal anti-Dengue virus antibody was used as a non-relevant control. The HBOH2 monoclonal antibody was generated against a 52 kDa recombinant HAAH polypeptide and recognizes the catalytic domain of beta-hydroxylase from mouse and human proteins. Polyclonal anti-HAAH antibodies cross-
10 react with rat hydroxylase protein. Control antibody anti-Erk-1 was purchased from Santa Cruz Biotechnology, Inc., CA. Sheep anti-mouse and donkey anti-rabbit antisera labeled with horseradish peroxidase were obtained from Amersham, Arlington Heights, IL.

Constructs

15 The murine full length AAH construct (pNH376) and the site-directed mutation construct (pNH376-H660) with abolished catalytic activity were cloned into the eukaryotic expression vector pcDNA3 (Invitrogen Corp., San Diego, CA). The full length human AAH was cloned into prokaryotic expression vector pBC-SK+ (Stratagene, La Jolla, CA). The full length human AAH (GENBANK Accession No. S83325) was
20 subcloned into the EcoRI site of the pcDNA3 vector.

Animal model of bile duct proliferation

Rats were divided into 9 separate groups of 3 animals each except for group 9, which contained 5 rats. Group 1 was the non-surgical control group, and group 2 was the sham-operated surgical control. The remaining groups underwent common bile duct
25 ligation to induce intrahepatic bile duct proliferation and were evaluated at 6, 12, 24, 48 hours and 4, 8 and 16 days as shown in Table 3. Animals were asphyxiated with CO₂, and liver samples were taken from left lateral and median lobes, fixed in 2 %

paraformaldehyde and embedded in paraffin. Liver samples (5 m) were cut and stained with hematoxylin and eosin to evaluate intrahepatic bile duct proliferation.

Immunohistochemistry was performed with polyclonal anti-HAAH antibodies that cross-react with the rat protein to determine levels of protein expression.

5 Bile duct proliferation associated with primary sclerosing cholangitis (PSC)

Liver biopsy samples were obtained from 7 individuals with PSC and associated bile duct proliferation. These individuals were evaluated according to standard gastroenterohepatological protocols. Patients were 22-46 years of age and consisted of 4 males and 3 females. Four had associated inflammatory bowel disease (3 ulcerative
10 colitis and 1 Crohn's colitis). All patients underwent a radiological evaluation including abdominal ultrasonography and endoscopic retrograde cholangiopancreatography to exclude the diagnosis of extrahepatic biliary obstruction. Tissue sections were prepared from paraffin embedded blocks and were evaluated by hematoxylin and eosin staining for bile duct proliferation. Expression of HAAH was determined by immunohistochemistry
15 using an HAAH-specific monoclonal antibody such as FB50.

Immunohistochemistry

Liver tissue sections (5 µm) were deparaffinized in xylene and rehydrated in graded alcohol. Endogenous peroxidase activity was quenched by a 30-minute treatment with 0.6 % H₂O₂ in 60% methanol. Endogenous biotin was masked by incubation with
20 avidin-biotin blocking solutions (Vector Laboratories, Burlingame, CA). The FB50 mAb (for PSC samples) and polyclonal anti-HAAH-hydroxylase antibodies (for rat liver samples) were added to slides in a humidified chamber at 4°C overnight.

Immunohistochemical staining was performed using a standard avidin-biotin horseradish peroxidase complex (ABC) method using Vectastain Kits with diaminobenzidine (DAB)
25 as the chromogen according to manufacturer's instructions (Vector Laboratories, Inc., Burlingame, CA). Tissue sections were counterstained with hematoxylin, followed by dehydration in ethanol. Sections were examined by a light microscopy for bile duct

- proliferation and HAAH protein expression. Paraffin sections of cholangiocarcinoma and placenta were used as positive controls, and hepatosteatoses samples were used as negative controls. To control for antibody binding specificity, adjacent sections were immunostained in the absence of a primary antibody, or using non-relevant antibody to
- 5 Dengue virus. As a positive control for tissue immunoreactivity, adjacent sections of all specimens were immunostained with monoclonal antibody to glyceraldehyde 3-phosphate dehydrogenase.

Western blot analysis

- Cell lysates were prepared in a standard radioimmunoprecipitation assay
- 10 (RIPA) buffer containing protease inhibitors. The total amount of protein in the lysates was determined by Bio-Rad colorimetric assay (Bio Rad, Hercules, CA) followed by 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to PVDF membranes, and subjected to Western blot analysis using FB50, HBOH2, anti-Erk-1 (used as an internal control for protein loading) as primary, sheep anti-mouse
- 15 and donkey anti-rabbit antisera labeled with horseradish peroxidase as secondary antibodies. Antibody binding was detected with enhanced chemiluminescence reagents (SuperSignal, Pierce Chemical Company, Rockford, IL) and film autoradiography. The levels of immunoreactivity were measured by volume densitometry using NIH Image software.

20 Enzymatic activity assay

- AAH activity was measured in cell lysates using the first EGF-like domain of bovine protein S as substrate where ^{14}C -labeled alpha-ketoglutarate hydroxylates the domain releasing ^{14}C containing CO_2 according to standard methods, e.g., those described by Jia et al., 1992, J. Biol. Chem. 267:14322-14327; Wang et al., 1991, J. Biol. Chem.
- 25 266:14004-14010; or Gronke et al., 1990, J. Biol. Chem. 265:8558-8565. Incubations were carried out at 37°C for 30 min in a final volume of 40 μl containing 48 μg of crude cell extract protein and 75 μM EGF substrate.

Cell transfection studies

The NIH-3T3 cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Mediatech, Washington, DC) supplemented with 10 % heat-inactivated fetal calf serum (FCS; Sigma Chemical Co., St.Louis, MO), 1% L-glutamine, 5 1% non-essential amino acids and 1% penicillin-streptomycin (GIBCO BRL, Life Technologies, Inc., Grand Island, NY). Subconfluent NIH-3T3 cells (3×10^5 cells/60-mm dish) were transfected with 10 μ g of one of the following plasmids: 1) non-recombinant pcDNA3 vector (Invitrogen Corp., San Diego, CA) as a negative control; 2) pNH376-H660, the murine AAH cDNA that was mutated in the catalytic 10 domain and cloned into the pcDNA3 vector driven by a CMV promoter; 3) pNH376, the wild type murine AAH cDNA cloned into the pcDNA3 vector; 4) pCDHH, wild type human AAH cDNA cloned into the pcDNA3 vector; or 5) pLNCX-UP1, a cDNA that encodes v-Src oncogene (positive control). Cells were transfected using the calcium phosphate transfection kit according to manufacturer's instructions (5 Prime - 3 Prime, 15 Inc., Boulder, CO). Comparison of cellular transfection efficiency was assessed with the various constructs. For this procedure, confluent plates obtained 48 hours after transfection were split and reseeded into 12 separate 6-cm dishes, and 6 of them were made to grow in the presence of 400 μ g/ml G-418 (GIBCO BRL, Life Technologies, Inc., Grant Island, NY) containing medium. The number of G-418 resistant foci was 20 determined at 14 days after transfection and used to correct for any variability in transfection efficiency.

Transformation assay

The NIH-3T3 cells were transfected with the various constructs and allowed to reach confluence after 48 hours as described above. Each 6 cm dish was split and 25 seeded into 12 different 6 cm dishes. While 6 of them were made to grow in the presence of G-418 to detect transfection efficiency, the other six were grown in complete medium without G-418 and with a medium change every 4th day. The number of transformed

foci were counted in these plates without G-418 and expressed as transformed foci per μg transfected DNA.

Anchorage-independent cell growth assay

A limiting dilution technique (0.15 cell/well of a flat bottom 96-well-plate) was performed on transfectants grown in G-418 in order to isolate cell clones with different levels of HAAH activity as measured by Western blot analysis and enzymatic assay of hydroxylase activity. Cloned cell lines (1.0×10^4 cells) were suspended in complete medium containing 0.4 % low-melting agarose (SeaPlaque GTG Agarose; FMC Bioproducts, Rockland, Maine) and laid over a bottom agar mixture consisting of complete medium with 0.53 % low-melting agarose. Each clone was assayed in triplicate. The clones were seeded under these conditions and 10 days later the size (positive growth > 0.1 mm in diameter) and number of foci were determined.

Tumorigenicity in nude mice

The same clones as assessed in the anchorage independent growth assay were injected into nude mice and observed for tumor formation. Tumorigenicity was evaluated using 10 animals in each of 4 groups (Charles River Labs., Wilmington, MA). Group 1 received 1×10^7 cells stably transfected with mock DNA, Group 2-4 received 1×10^7 cells of clones stable transfected with pNH376 and expressing various levels of murine HAAH protein. Nude mice were kept under pathogen-free conditions in a standard animal facility. Thirty days after tumor cell inoculation, the animals were sacrificed using isofluorane (Aerrane, Anaquest, NJ) containing chambers and the tumors were carefully removed and weight determined.

Animal model of bile duct proliferation

Following ligation of the common bile duct, intrahepatic bile duct proliferation was evident at 48 hours. Tissue samples obtained 8 and 16 days following common bile duct ligation revealed extensive bile duct proliferation as shown in Table 3.

**Table 3: Bile duct proliferation and HAAH expression
at different intervals after common bile duct ligation**

Group	Surgical Procedure	Microscopy*	Immunohisto-chemistry
1	no surgery	normal	negative
2	sham surgery	normal	negative
3	6 hours post ligation	normal	negative
4	12 hours post ligation	normal	negative
5	24 hours post ligation	normal	negative
6	48 hours post ligation	minimal bile duct prolif.	negative
7	4 days post ligation	moderate bile duct prolif.	negative
8	8 days post ligation	extensive bile duct prolif.	negative
9	16 days post ligation	extensive bile duct prolif.	negative

* Investigation was performed under light microscopy following a hematoxylin and eosin staining.

Immunohistochemical staining failed to detect presence of HAAH in proliferating bile ducts at any time. Analysis of HAAH expression in bile ducts derived from sham surgical controls was also negative, while all samples exhibited positive immunoreactivity with control antibodies to glyceraldehyde 3-phosphate dehydrogenase.

5 Thus, bile duct proliferation was not associated with increased HAAH expression in this standard animal model system.

HAAH expression in PSC

The liver biopsy specimens from patients with PSC exhibited bile duct proliferation accompanied by periductal fibrosis and a mononuclear inflammatory cell

10 infiltrate without evidence of dysplasia. Adjacent sections immunostained with the an HAAH-specific monoclonal antibody had no detectable HAAH immunoreactivity in proliferating bile ducts. In contrast, sections of cholangiocarcinoma that were immunostained simultaneously using the same antibody and detection reagents manifested intense levels of HAAH immunoreactivity in nearly all tumor cells, whereas

15 adjacent sections of the cholangiocarcinomas exhibited a negative immunostaining reaction with monoclonal antibody to Dengue virus. These findings indicate that HAAH expression was associated with malignant transformation rather than non-cancerous cellular proliferation of intrahepatic bile ducts.

HAAH associated transformation of NIH-3T3 cells

The transforming capability of the murine and human AAH genes, as well as the murine AAH mutant construct without enzymatic activity were compared to mock DNA (negative control) and v-Src transfected NIH-3T3 cells (positive control). The transforming capability of murine AAH was found to be 2-3 times that of vector DNA control as shown in Fig. 1. The transforming capacity of the human gene was greater than that observed with the murine AAH (32 ± 1.5 versus 13 ± 2.6 transformed foci, respectively). The murine and human AAH transfected cells formed large foci, resembling those of v-Src transfected fibroblasts, compared to the occasional much smaller foci observed in cells transfected with vector DNA that displayed the contact inhibition of fibroblast cell lines. Parallel experiments performed using the mutant pNH376-H660 construct without enzymatic activity revealed no transforming activity. This finding indicates that the enzymatic activity of HAAH is required for the transforming activity exhibited by the HAAH gene.

Anchorage-independent cell growth assay

After transient transfection with the murine AAH construct, several different transformed foci were isolated for dilutional cloning experiments to establish stable transfected cell clones with different levels of HAAH gene expression. Nine different cloned cell lines were selected for further study. The expression level of the HAAH protein was determined by Western blot analysis. Clones 7 and 18 had a modest increase in HAAH protein expression, yet formed large colonies in soft agar (Fig. 2). Protein loading was equivalent in all lanes as shown by immunoblotting of the same membranes with an anti-Erk-1 monoclonal antibody. The increased protein expression was associated with increased enzymatic activity as shown in Fig. 3. The capability of these clones to exhibit anchorage independent cell growth in soft agar is presented in Fig. 3. All 3 clones with increased HAAH gene expression demonstrated anchorage independent cell growth compared to the mock DNA transfected clone.

Tumor formation in nude mice

The 3 clones with increased HAAH gene expression were evaluated for the ability to form tumors in nude mice. Tumor size in the mouse given clone 18 was compared to a mock DNA transfected clone. Clones 7, 16 and 18 were highly transformed in this assay and produced large tumors with a mean weight of 2.5, 0.9 and 1.5 grams, respectively (Fig. 4). These data indicate that overexpression of HAAH contributes to induction and maintenance of the malignant phenotype *in vivo*.

High level HAAH expression is indicative of malignancy

In order to determine if HAAH expression was associated with malignancy rather than increased cell turnover, two models of bile duct proliferation were studied. In the animal model, ligation of the common bile duct induced extensive intrahepatic bile duct proliferation, yet there was no evidence of HAAH gene expression under these experimental conditions as shown in Table 3. Similarly, HAAH gene expression was assessed in a human disease model associated with bile duct proliferation since PSC is an autoimmune liver disease associated with destruction as well as proliferation of the intra and extrahepatic bile ducts. PSC is premalignant disease, and a significant proportion of affected individuals will eventually develop cholangiocarcinoma. However, no evidence for increased HAAH gene expression in the presence of extensive bile duct proliferation.

Having established that HAAH protein levels were elevated in cholangiocarcinoma and not in normal or proliferating bile ducts, the role of HAAH in the generation of a malignant phenotype was studied. The HAAH gene was transfected into NIH-3T3 cells and cellular changes, e.g., increased formation of transformed foci, colony growth in soft agar and tumor formation in nude mice associated with malignant transformation, were evaluated. The full-length murine and human AAH genes were cloned into expression constructs and transiently transfected into NIH-3T3 cells. An increased number of transformed foci was detected in cells transfected both with the murine and human AAH genes as compared to mock DNA transfected controls. The increased number of transformed foci, after controlling for transfection efficiency, was not as high compared to v-Src gene transfected cells used as a positive control. The enzymatic activity of the HAAH gene was required for a malignant phenotype because a mutant construct which abolished the catalytic site had no transforming properties. Several stable transfectants and cloned NIH-3T3 cell lines with a modest increase in HAAH protein levels and enzymatic activity were established. Such cell lines were placed in soft agar to examine anchorage independent cell growth as another property of the malignant phenotype. All cell lines grew in soft agar compared to mock DNA transfected control, and there was a positive correlation between the cellular level of HAAH gene expression and the number and size of colonies formed. Three of these cloned cell lines formed tumors in nude mice. All three cell lines with increased HAAH expression were oncogenic as shown by the development of large tumors as another well-known characteristic of the transformed phenotype.

To determine whether cellular changes induced by overexpression of HAAH were related to the enzymatic function, a site-directed mutation was introduced into the gene that changed the ferrous iron binding site from histidine to lysine at 660th position of mouse HAAH thereby abolishing hydroxylase activity of the murine HAAH. A
5 corresponding mutation in HAAH is used as a dominant negative mutant to inhibit HAAH hydroxylase activity. The pNH376-H660 construct had no transformation activity indicating cellular changes of the malignant phenotype induced by overexpression depends on the enzymatic activity of the protein.

Notch receptors and their ligands have several EGF-like domains in the
10 N-terminal region that contain the putative consensus sequence for beta-hydroxylation. Notch ligands are important elements of the Notch signal transduction pathway and interaction of Notch with its ligands occurs by means of EGF-like domains of both molecules. Point mutations affecting aspartic acid or asparagine residues in EGF-like domains that are the targets for beta-hydroxylation by HAAH reduce calcium binding and
15 protein-protein interactions involved in the activation of downstream signal transduction pathways. Overexpression of HAAH and Notch protein hydroxylation by HAAH contributes to malignancy. Tumor growth is inhibited by decreasing Notch protein hydroxylation by HAAH.

10 The data presented herein is evidence that high-level HAAH expression is
linked to malignant transformation. An increase in expression of the HAAH cDNA in
NIH-3T3 cells induced a transformed phenotype manifested by increased numbers of
transformed foci, anchorage-independent growth, and tumorigenesis in nude mice. In
5 addition, intact HAAH-enzyme was found to be required for HAAH-associated
transformation. Accordingly, inhibition of as little as 20% of endogenous HAAH
enzymatic activity or expression confers a therapeutic benefit. For example, clinical
benefit is achieved by 50%-70% inhibition of HAAH expression or activity after
administration of an HAAH inhibitory compound compared to the level associated with
10 untreated cancer cell or a normal noncancerous cell.

HAAH is regulated at the level of transcription. Only modest increases in
HAAH expression and enzyme activity were required for cellular transformation. These
results indicate that increased HAAH gene expression and enzyme activity contribute to
the generation or maintenance of the transformed phenotype and that decreasing
15 transcription of the HAAH gene or decreasing enzymatic activity of the HAAH gene
product leads to a decrease in malignancy. Accordingly, HAAH transcription is inhibited
by administering compounds which decrease binding of Fos and/or Jun (elements which
regulate HAAH transcription) to HAAH promoter sequences.

Since HAAH is up-regulated with malignant transformation of bile duct
20 epithelium, and HAAH immunoreactivity is detectable on tumor cell surface membranes,
HAAH is also a molecule to which to target a cytotoxic agent, e.g., by linking the
cytotoxic agent to a compound that binds to HAAH expressed on the surface of a tumor
cell. Assay of HAAH protein levels in either biological fluids such as bile, or cells
obtained by fine needle aspiration is a diagnostic marker of human cholangiocarcinoma.

25 Example 2: Expression of AAH and growth and invasiveness of malignant CNS
neoplasms

AAH is abundantly expressed in carcinomas and trophoblastic cells, but not in most normal cells, including those of CNS origin. High levels of AAH expression were observed in 15 of 16 glioblastomas, 8 of 9 anaplastic oligodendrogliomas, and 12 of 12 primitive neuroectodermal tumors (PNETs). High levels of AAH immunoreactivity were

5 primarily localized at the infiltrating edges rather than in the central portions of tumors. Double-label immunohistochemical staining demonstrated a reciprocal relationship between AAH and tenascin, a substrate for AAH enzyme activity. PNET2 neuronal cell lines treated with phorbol ester myristate or retinoic acid to stimulate neuritic extension and invasive growth exhibited high levels of AAH expression, whereas H_2O_2 -induced

10 neurite retraction resulted in down-regulation of AAH. PNET2 neuronal cells that stably over-expressed the human AAH cDNA had increased levels of PCNA and Bcl-2, and reduced levels of p21/Waf1 and p16, suggesting that AAH overexpression results in enhanced pathological cell proliferation, cell cycle progression, and resistance to apoptosis. In addition, the reduced levels of p16 observed in AAH-transfectants indicate

15 that AAH over-expression confers enhanced invasive growth of neoplastic cells since deletion or down-regulation of the p16 gene correlates with more aggressive and invasive in vivo growth of glioblastomas. Increased AAH immunoreactivity was detected at the infiltrating margins of primary malignant CNS neoplasms, further indicating a role of HAAH in tumor invasiveness.

20 The following materials and methods were used to generate the data described below.

25

Analysis of AAH Immunoreactivity in Primary Human Malignant CNS

Neoplasms:

AAH immunoreactivity was examined in surgical resection specimens of glioblastoma (N=16), anaplastic oligodendroglioma (N=9), and primitive
5 neuroectodermal tumor (PNET; supratentorial neuroblastomas (N=3) and medulloblastomas (N=9). The histopathological sections were reviewed to confirm the diagnoses using standard criteria. Paraffin sections from blocks that contained representative samples of viable solid tumor, or tumor with adjacent intact tissue were studied. Sections from normal adult postmortem brains (N=4) were included as negative
10 controls. AAH immunoreactivity was detected using qn HAAH-specific monoclonal antibody. Immunoreactivity was revealed by the avidin-biotin horseradish peroxidase complex method (Vector ABC Elite Kit; Vector Laboratories, Burlingame, CA) using 3-3' diaminobenzidine (DAB) as the chromogen (24) and hematoxylin as a counterstain.

Tenascin and laminin are likely substrates for AAH due to the presence of
15 EGF-like repeats within the molecules. Double-immunostaining studies were performed to co-localize AAH with tenascin or laminin. The AAH immunoreactivity was detected by the ABC method with DAB as the chromogen, and tenascin or laminin immunoreactivity was detected by the avidin-biotin alkaline phosphatase complex method (Vector Laboratories, Burlingame, CA) with BCIP/NBT as the substrate. As
20 positive and negative controls, adjacent sections were immunostained with monoclonal antibody to glial fibrillary acidic protein (GFAP) and Hepatitis B surface antigen. All specimens were batch immunostained using the same antibody dilutions and immunodetection reagents.

25

Cell Lines and Culture Conditions

Studies were conducted to determine whether AAH expression was modulated with neurite (filopodia) extension (sprouting) as occurs with invasive growth of malignant neoplasms. Human PNET2 CNS-derived and SH-Sy5y neuroblastoma cells were cultured and stimulated for 0, 1, 2, 3, 5, or 7 days with 100 nM phorbol 12-ester 13-acetate or 10 μ M retinoic acid to induce sprouting. In addition, to examine the effects of neurite retraction on AAH expression, subconfluent cultures were treated for 24 hours with low concentrations (10-40 μ M) of H_2O_2 . For both studies, AAH expression was evaluated by Western blot analysis using the an HAAH-specific antibody.

10 Generation of PNET2 AAH-transfected Clones

The full-length human AAH cDNA (SEQ ID NO:3) was ligated into the pcDNA3.1 mammalian expression vector in which gene expression was under the control of a CMV promoter (Invitrogen Corp., San Diego, CA). PNET2 cells were transfected with either pHAAH or pcDNA3 (negative control) using Cellfectin reagent (Gibco BRL, 15 Grand Island, NY). Neomycin-resistant clones were selected for study if the constitutive levels of AAH protein expression were increased by at least two-fold relative to control (pcDNA3) as detected by Western blot analysis. To determine how AAH overexpression altered the expression of genes that modulate the transformed phenotype, the levels of proliferating cell nuclear antigen (PCNA), p53, p21/Waf1, Bcl-2, and p16 were measured 20 in cell lysates prepared from subconfluent cultures of AAH (N=5) and pcDNA3 (N=5) stably transfected clones. PCNA was used as marker of cell proliferation. p53, p21/Waf1, and Bcl-2 levels were examined to determine whether cells that over-expressed AAH were more prone to cell cycle progression and more resistant to apoptosis. The levels of p16 were assessed to determine whether AAH over-expression 25 has a role in tumor invasiveness.

Western blot analysis

Cells grown in 10 cm² dishes were lysed and homogenized in a standard radioimmunoprecipitation assay RIPA buffer containing protease and phosphatase inhibitors. The supernatants collected after centrifuging the samples at 12,000 x g for 10 minutes to remove insoluble debris were used for Western blot analysis. Protein concentration was measured using the BCA assay (Pierce Chemical Co, Rockford, IL). Samples containing 60 µg of protein were electrophoresed in sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE) and subjected to Western blot analysis. Replicate blots were probed with the individual antibodies. Immunoreactivity was detected with horseradish peroxidase conjugated IgG (Pierce Chemical Co, Rockford, IL) and enhanced chemiluminescence reagents. To quantify the levels of protein expression, non-saturated autoradiographs were subjected to volume densitometry using NIH Image software, version 1.6. Statistical comparisons between pHAH and pcDNA3 transfected cells were made using Student T tests.

Antibodies

HAAH-specific monoclonal antibody generated against the FOCUS hepatocellular carcinoma cells were used to detect AAH immunoreactivity. Monoclonal antibodies to tenascin, and glial fibrillary acidic protein, and rabbit polyclonal antibody to laminin were purchased from Sigma Co. (St. Louis, MO). Rabbit polyclonal antibody to human p16 was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). The 5C3 negative control monoclonal antibody to Hepatitis B surface antigen was generated using recombinant protein and used as a negative control.

25

AAH immunoreactivity in primary malignant brains tumors

AAH immunoreactivity was detected in 15 of 16 glioblastomas, 8 of 9 anaplastic oligodendrogliomas, and all 12 PNETs. AAH immunoreactivity was localized in the cytoplasm, nucleus, and cell processes. The tissue distribution of AAH immunoreactivity was notable for the intense labeling localized at the interfaces between tumor and intact brain, and the conspicuously lower levels of immunoreactivity within the central portions of the tumors. High levels of AAH immunoreactivity were also observed in neoplastic cells distributed in the subpial zones, leptomeninges, Virchow-Robin perivascular spaces, and in individual or small clusters of neoplastic cells that infiltrated the parenchyma. In contrast, AAH immunoreactivity was not detectable in normal brain. The distribution of AAH immunoreactivity appeared not to be strictly correlated with DNA synthesis since the density of nuclei in mitosis (1-5%) was similar in the central and peripheral portions of the tumors.

15 Relationship between AAH and tenascin immunoreactivity in glioblastomas

WU 01/35104 PC 17/0300/30730

Tenascin is an extracellular matrix-associated antigen expressed in malignant gliomas. Tenascin contains EGF-like domains within the molecule, a substrate for HAAH hydroxylation. To localize AAH in relation to tenascin immunoreactivity in malignant brain tumors, double-label immunohistochemical staining was performed in which AAH was detected using a brown chromogen (DAB), and tenascin, a blue chromogen (BCIP/NBT). Adjacent sections were similarly double-labeled to co-localize AAH with laminin, another EGF domain containing extracellular matrix molecule expressed in the CNS. Intense levels of tenascin immunoreactivity were observed in perivascular connective tissue and in association with glomeruloid proliferation of endothelial cells. The double-labeling studies demonstrated a reciprocal relationship between AAH and tenascin immunoreactivity such that high levels of AAH were associated with low or undetectable tenascin, and low levels of AAH were associated with abundant tenascin immunoreactivity. Although laminins are also likely substrates for AAH enzyme activity due to the EGF repeats within the molecules, double labeling studies revealed only low levels of laminin immunoreactivity throughout the tumors and at interfaces between tumor and intact tissue.

20

25

Analysis of AAH expression in neuronal cell lines treated with PMA or RA

Neuritic sprouting/filopodia extension marks invasive growth of neoplastic neuronal cells. PMA activates protein kinase C signal transduction pathways that are involved in neuritic sprouting. Retinoic acid binds to its own receptor and the

5 ligand-receptor complex translocates to the nucleus where it binds to specific consensus sequences present in the promoter/enhancer regions of target genes involved in neuritic growth. Both PNET2 and SH-Sy5y cells can be induced to sprout by treatment with PMA (60-120 nM) or retinoic acid (5-10 μ M). Figs. 5A-D depict data from representative Western blot autoradiographs; the bar graphs correspond to the mean \pm

10 S.D. of results obtained from three experiments. Western blot analysis with the FB50 antibody detected doublet bands corresponding to protein with an molecular mass of approximately 85 kDa. Untreated PNET2 cells had relatively low levels of AAH immunoreactivity (Fig. 5A), whereas untreated SH-Sy5y cells had readily detected AAH expression (Fig. 5B). Untreated PNET2 cells exhibited polygonal morphology with

15 coarse, short radial cell processes, whereas SH-Sy5y cells were slightly elongated and spontaneously extend fine tapered processes. Both cell lines manifested time-dependent increases in the levels of AAH immunoreactivity following either RA (Figs. 5A and 5B) or PMA (Fig. 5C) stimulation and neurite extension. In PNET2 cells, the levels of AAH protein increased by at least two-fold 24 hours after exposure to RA or PMA, and high

20 levels of AAH were sustained throughout the 7 days of study. In SH-Sy5y cells, the RA- or PMA-stimulated increases in AAH expression occurred more gradually and were highest after 7 days of treatment (Fig. 5B).

To examine the effect of AAH expression on neurite retraction, PNET2 and SH-Sy5y cells were treated with low concentrations (8-40 μ M) of H_2O_2 . After 24 hours exposure to up to 40 μ M H_2O_2 , although most cells remained viable (Trypan blue dye exclusion), they exhibited neurite retraction and rounding. Western blot analysis using the FB50 antibody demonstrated H_2O_2 dose-dependent reductions in the levels of AAH protein (Fig. 5D).

Effects of AAH over-expression in PNET2 cells

To directly assess the role of AAH overexpression in relation to the malignant phenotype, PNET2 cells were stably transfected with the human full-length cDNA with gene expression under control of a CMV promoter (pHAAH). Neomycin-resistant clones that had at least two-fold higher levels of AAH immunoreactivity relative to neomycin-resistant pcDNA3 (mock) clones were studied. Since aggressive behavior of malignant neoplasms is associated with increased DNA synthesis, cell cycle progression, resistance to apoptosis, and invasive growth, the changes in phenotype associated with constitutive over-expression of AAH were characterized in relation to PCNA, p21/Waf1, p53, Bcl-2, and p16. PCNA was used as an index of DNA synthesis and cell proliferation. p21/Waf1 is a cell cycle inhibitor. Expression of the p53 tumor-suppressor gene increases prior to apoptosis, whereas bcl-2 inhibits apoptosis and enhances survival of neuronal cells. p16 is an oncosuppressor gene that is often either down-regulated or mutated in infiltrating malignant neoplasms.

Five pHAAH and 5 pcDNA3 clones were studied. Increased levels of AAH expression in the pHAAH transfected clones was confirmed by Western (Fig. 6) and Northern blot analyses. Western blot analysis using cell lysates from cultures that were 70 to 80 percent confluent demonstrated that constitutively increased levels of AAH expression (approximately 85 kDa; $P < 0.05$) in pHAAH-transfected cells were associated with significantly increased levels of PCNA (approximately 35 kDa; $P < 0.01$) and Bcl-2 (approximately 25 kDa; $P < 0.05$), and reduced levels of p21/Waf1 (approximately 21

kDa; $P < 0.001$) and p16 (approximately 16 kDa; $P < 0.001$) (Fig. 6). However, the pHAAH stable transfectants also exhibited higher levels of wild-type p53 (approximately 53-55 kDa). Although AAH expression (85 kDa protein) in the stable transfectants was increased by only 75 to 100 percent, the levels of p16 and p21/Waf1 were sharply
5 reduced, and PCNA increased by nearly two-fold (Fig. 6).

Increased AAH expression is indicative of growth and invasiveness of malignant CNS neoplasms

The data described herein demonstrates that AAH overexpression is a diagnostic tool by which to identify primary malignant CNS neoplasms of both neuronal
10 and glial cell origin. Immunohistochemical staining studies demonstrated that AAH overexpression was detectable mainly at the interfaces between solid tumor and normal tissue, and in infiltrating neoplastic cells distributed in the subpial zones, leptomeninges, perivascular spaces, and parenchyma. *In vitro* experiments demonstrated that AAH gene expression was modulated with neurite (filopodium) extension and invasiveness and
15 down-regulated with neurite retraction. In addition, PNET2 cells stably transfected with the AAH cDNA exhibited increased PCNA and bcl-2, and reduced Waf1/p21 and p16 expression. Therefore, AAH overexpression contributes to the transformed phenotype of CNS cells by modulating the expression of other genes that promote cellular proliferation and cell cycle progression, inhibit apoptosis, or enhance tumor cell invasiveness.

20 The data demonstrated readily detectable AAH mRNA transcripts (4.3 kB and 2.6 kB) and proteins (85 kDa and 50-56 kDa) in PNET2 and SH-Sy5y cells, but not in normal brain. Correspondingly, high levels of AAH immunoreactivity were observed in 35 of the 37 in malignant primary CNS-derived neoplasms studied, whereas the 4 normal control brains had no detectable AAH immunoreactivity. The presence of high-level
25 AAH immunoreactivity at the infiltrating margins and generally not in the central portions of the tumors indicates that AAH overexpression is involved in the invasive growth of CNS neoplasms. Administration of compounds which decrease AAH

expression or enzymatic activity inhibits proliferation of CNS tumors which overexpress AAH, as well as metastases of CNS tumors to other tissue types.

The AAH enzyme hydroxylates EGF domains of a number of proteins.

5 Tenascin, an extracellular matrix molecule that is abundantly expressed in malignant gliomas, contains EGF-like domains. Since tenascin promotes tumor cell invasion, its abundant expression in glioblastomas represents an autocrine mechanism of enhanced tumor cell growth vis-a-vis the frequent overexpression of EGF or EGF-like receptors in malignant glial cell neoplasms. Analysis of the functional domains of tenascins indicated that the mitogenic effects of this family of molecules are largely mediated by the
10 fibronectin domains, and that the EGF-like domains inhibit growth, cell process elongation, and matrix invasion. Therefore, hydroxylation of the EGF-like domains by AAH represents an important regulatory factor in tumor cell invasiveness.

Double-label immunohistochemical staining studies demonstrated a reciprocal relationship between AAH and tenascin immunoreactivity such that high levels AAH
15 immunoreactivity present at the margins of tumors were associated with low levels of tenascin, and low levels of AAH were often associated with high levels of tenascin. These observations indicated that AAH hydroxylation of EGF-like domains of tenascin alters the immunoreactivity of tenascin protein, and in so doing, facilitates the invasive growth of malignant CNS neoplasms into adjacent normal tissue and perivascular spaces.

20

AAH immunoreactivity was examined in PNET2 and SH-Sy5y neuronal cells induced to undergo neurite extension with PMA or retinoic acid, or neurite retraction by exposure to low doses of H_2O_2 . AAH expression was sharply increased by PMA- or retinoic acid-induced neurite (filopodium) extension, and inhibited by H_2O_2 -induced
25 neurite retraction and cell rounding. Neurite or filopodium extension and attachment to extracellular matrix are required for tumor cell invasion in the CNS. The EGF-like domains of tenascin inhibit neuritic and glial cell growth into the matrix during

development.

To directly examine the role of AAH overexpression in relation to the transformed phenotype, genes modulated with DNA synthesis, cell cycle progression, apoptosis, and tumor invasiveness were examined in neuronal cell clones that stably over-expressed the human AAH cDNA. The findings of increased PCNA and reduced Waf1/p21 immunoreactivity indicated that AAH overexpression enhances cellular proliferation and cell cycle progression. In addition, the finding of increased Bcl-2 expression indicated that AAH overexpression contributes to the transformed phenotype by increasing cellular resistance to apoptosis. The apparently contradictory finding of higher levels of p53 in the cells that overexpressed AAH is explained by the observation that high levels of wildtype p53 in immature neuronal cells were associated with neuritic growth (invasiveness) rather than apoptosis. Levels of p16 were reduced (compared to normal cells) or virtually undetectable in cells that constitutively overexpressed AAH; a deletion mutation of the p16 gene has been correlated with invasive growth and more rapid progression of malignant neoplasms, including those of CNS origin. These data indicate that p16 expression is modulated by AAH.

Example 3: Increased HAAH production and IRS-mediated signal transduction

IRS-1 mediated signal transduction pathway is activated in 95% of human HCC tumors compared to the adjacent uninvolved liver tissue. HAAH is a downstream effector gene involved in this signal transduction pathway. HAAH gene upregulation is closely associated with overexpression of IRS-1 in HCC tumors as revealed by immunohistochemical staining and Western blot analysis. A high level of HAAH protein is expressed in HCC and cholangiocarcinoma compared to normal hepatocytes and bile ducts. Both of these tumors also exhibit high level expression of IRS-1 by immunohistochemical staining. FOCUS HCC cell clones stably transfected with a C-terminal truncated dominant negative mutant of IRS-1, which blocks insulin and IGF-1 stimulated signal transduction, was associated with a striking reduction in HAAH gene

- expression in liver. In contrast, transgenic mice overexpressing IRS-1 demonstrate an increase in HAAH gene expression by Western blot analysis. Insulin stimulation of FOCUS HCC cells (20 and 40 U) in serum free medium and after 16 hr of serum starvation demonstrated upregulation of HAAH gene expression. These data indicate that
- 5 HAAH gene expression is a downstream effector of the IRS-1 signal transduction pathway.

Example 4: Effects of HAAH expression levels on the characteristics of the malignant phenotype

- Overexpression of IRS-1 in NIH 3T3 cells induces transformation. The
- 10 full-length murine HAAH construct was cloned into the pcDNA3 eukaryotic expression vector. A second murine construct encoded HAAH with abolished catalytic activity due to a site directed mutation. The full-length human HAAH cDNA was cloned into the pcDNA3 expression vector as well as a plasmid that encodes v-src which was used as a positive control for transformation activity. Standard methods were used for transfection
- 15 of NIH 3T3 cells, control for transfection efficiency, assays of HAAH enzymatic activity, transformation by analysis of foci formation, anchorage-independent cell growth assays and analysis of tumorigenicity in nude mice. The data indicated that HAAH overexpression is associated with generation of a malignant phenotype.

Table 4: Overexpression of enzymatically active HAAH

indicates malignancy

cDNA	# of foci \pm S.D. ^b	NIH 3T3 clone	# of colonies ^c
pcDNA3 (mock)	6.0 ± 3.3	PcDNA (mock)	0.4 ± 0.5
murine HAAH	14.0 ± 2.9	clone 18 ^d	6.2 ± 2.9
mutant murine HAAH ^a	1.6 ± 1.0	clone 16 ^e	4.7 ± 6.5
human HAAH	32.0 ± 5.4		
v-scr	98.0 ± 7.1		

a. enzymatically inactive HAAH

b. $P < 0.01$ compared to mock and mutant murine HAAH

5 c. $P < 0.001$ compared to mock

d. Clone 18 is a stable cloned NIH 3T3 cell line that overexpression human HAAH by approximately two fold.

e. Clone 16 is a stable cloned NIH 3T3 cell line that overexpresses human HAAH by about 50%.

10 These data indicate that overexpression of HAAH is associated with formation of transformed foci. Enzymatic activity is required for cellular transformation to occur. Cloned NIH 3T3 cell lines with increased human HAAH gene expression grew as solid tumors in nude mice. HAAH is a downstream effector gene of the IRS-1 signal transduction pathway.

15 Example 5: Inhibition of HAAH gene expression

The FOCUS HCC cell line from which the human HAAH gene was initially cloned has a level of HAAH expression that is approximately 3-4 fold higher than that found in normal liver. To make an HAAH antisense construct, the full length human HAAH cDNA was inserted in the opposite orientation into a retroviral vector containing

a G418 resistant gene, and antisense RNA was produced in the cells. Shorter HAAH antisense nucleic acids, e.g., those corresponding to exon 1 of the HAAH gene are also used to inhibit HAAH expression.

FOCUS cells were infected with this vector and the level of HAAH was
5 determined by Western blot analysis. A reduction in HAAH gene expression was observed. Growth rate and morphologic appearance of cells infected with a retrovirus containing a nonrelevant Green Fluorescent Protein (GFP) also inserted in the opposite orientation as a control (Fig. 8). Cells (harboring the HAAH antisense construct) exhibited a substantial change in morphology characterized by an increase in the
10 cytoplasm to nuclear ratio as well as assuming cell shape changes that were reminiscent of normal adult hepatocytes in culture. Cells with reduced HAAH levels grew at a substantially slower rate than retroviral infected cells expressing antisense (GFP) (control) as shown in Fig. 8. A reduction in HAAH gene expression was associated with a more differentiated noncancerous "hepatocyte like" phenotype. Expression of HAAH
15 antisense sequences are used to inhibit tumor growth rate. Reduction of HAAH cellular levels results in a phenotype characterized by reduced formation of transformed foci, low level or absent anchorage independent growth in soft agar, morphologic features of differentiated hepatocytes as determined by light and phase contrast microscopy, and no tumor formation (as tested by inoculating the cells into nude mice).

20 Example 6: Inhibition of AAH expression by AAH antisense oligonucleotides

Oligonucleotides that inhibit AAH gene expression were designed and synthesized using standard methods. For example, antisense oligonucleotides (20 mers) were designed to bind to the 5' region of the AAH mRNA and overlap with the AUG initiation codon (Table 5). The antisense oligonucleotides were selected such that they
25 were complementary to sequences beginning 1 (Location -1), 6 (Location -6), or 11 (Location -11) nucleotides upstream (prior to) the "A" of the AUG (methionine) codon. In addition, a sense oligonucleotide beginning at Location -3 was made.

Table 5: Sequence of exemplary oligonucleotide molecules

Location (-1)

5' CAT TCT TAC GCT GGG CCA TT 3' (SEQ ID NO:10)

5 Location (-6)

5' TTA CGC TGG GCC ATT GCA CG 3' (SEQ ID NO:11)

Location (-11)

5' CTG GGC CAT TGC ACG GTC CG 3' (SEQ ID NO:12)

10

Sense

5' ATC ATG CAA TGG CCC AGC GTA A 3' (SEQ ID NO:13)

Fig. 10 shows the region of the AAH gene to which the antisense oligonucleotides described in Table 5 bind. All of the oligonucleotides were designed using MacVector

15 6.5.3 software.

AAH antisense oligonucleotides tested were found to inhibit AAH gene expression. Using an *in vitro* cell free transcription translation assay (TNT Quick Coupled System), the human AAH cDNA (pHAAH) was used to synthesize AAH protein. *In vitro* translation was achieved with rabbit reticulocyte lysate included in the reaction mixture. The translated product was labeled with [³⁵S] methionine in the presence of reaction buffer, RNA polymerase, amino acid mixture, and ribonuclease inhibitor (RNasin). The products were analyzed by SDS-PAGE followed by autoradiography. A luciferase (Luc) expressing plasmid was used as a positive control. In the second and third lanes, synthesis of the ~85 kD AAH protein is shown (AAH, arrow) using 1 or 2 micrograms of plasmid as the template and the T7 DNA-dependent RNA polymerase primer/promoter to generate mRNA. The addition of 100x or 1000x excess antisense oligonucleotide primer resulted in progressively greater degrees of inhibition of AAH protein synthesis, whereas the inclusion of the same amounts of sense oligonucleotide had no effect on AAH protein synthesis. Further studies demonstrated complete inhibition of AAH protein synthesis only with the antisense oligonucleotides.

In addition, effective inhibition of gene expression was observed using all three antisense oligonucleotides tested. Fig. 11 shows the results of an *in vitro* transcription/translation analysis of AAH antisense oligonucleotides and shows that the antisense oligonucleotides tested block translation of the HAAH RNA and subsequent protein synthesis of HAAH
5 protein.

Inhibition of AAH gene expression was also tested in cells. Fig. 11 shows the results of a Microtiter In situ Luminescence Quantification (MILQ) Assay and demonstrates the actual effect of the antisense oligonucleotides inside cells. Substantial reduction in HAAH gene expression was detected by simply adding the antisense
10 oligonucleotides to the culture medium of the cells. The MILQ assay quantifies *in situ* hybridization binding in cultured cells without the need for RNA extraction. The MILQ assay was used to study competitive antisense binding inhibition to illustrate that the antisense probe hybridized to the mRNA expressed endogenously within the Sh-SySy neuroblastoma cells. In this figure, inhibition of FITC-labeled Location -6 antisense
15 oligonucleotide binding using specific unlabeled antisense oligonucleotides is shown. Minimal inhibition of binding was observed using non-relevant oligonucleotides. The unlabeled specific oligonucleotide was capable of effectively competing for the binding site designated by the FITC-conjugated Location -6 probe, whereas the non-relevant probe exhibited significantly less inhibition at the same molar concentration. Bound
20 probe (FITC-labeled) was detected using horseradish peroxidase conjugated antibodies to FITC, and luminescence reagents were used to detect the bound antibody. Luminescence units were corrected for cell density and are arbitrary in nature. These data indicate that cells effectively take up antisense oligonucleotides in the surrounding environment and that the oligonucleotides taken up effectively and specifically inhibit HAAH gene
25 expression.

Inhibition of HAAH gene expression is enhanced by contacting cells with a phosphorothioate derivative of the HAAH antisense. Phosphorothioate antisense

- derivatives are made using methods well known in the art. Fig. 13 shows inhibition of AAH gene expression due to antisense (Location -6) oligonucleotide gene delivery into SH-Sy5 neuroblastoma cells. The MILQ assay was used to measure gene expression resulting from antisense oligonucleotide gene delivery. Cells were contacted with AAH
- 5 Location -6 antisense DNA, and AAH protein expression was measured using methods known in the art, e.g., the MICE assay (de la Monte, et al, 1999, Biotechniques), to determine if it was inhibited by hybridization with the oligonucleotide. The MICE assay is used to measure immunoreactivity in cultured cells without the need to extract proteins or perform gel electrophoresis. This assay is more sensitive than Western blot analysis.
- 10 Using the MICE assay, AAH immunoreactivity was assessed in cells transfected with non-relevant (random) oligonucleotide sequences, specific antisense oligonucleotides (Location -6), and a phosphorothioate Location -6 antisense oligonucleotide. Phosphorothioate chemical modification of the oligonucleotide was found to permit greater stability of the DNA inside the cell since the sulfur group protects the DNA from
- 15 the degradation that normally occurs with phosphodiester bonds and cellular nucleases. Antisense AAH oligonucleotide (Location -6) transfection resulted in reduced levels of AAH immunoreactivity, and using the phosphorothioate linked Location -6 antisense oligonucleotide, the effect of inhibiting AAH gene expression was substantial relative to the levels observed in cells transfected with the random oligonucleotide. The more
- 20 effective inhibition of AAH expression using the phosphorothioate-linked antisense oligonucleotide was likely due to the greater stability of the molecule combined, with retained effective binding to mRNA.

Example 7: Human IRS-1 mutants

Insulin/IGF-1 stimulated expression of HAAH in HCC cell lines.

- 25 Dominant-negative IRS-1 cDNAs mutated in the plextrin and phosphotyrosine (PTB) domains, and Grb2, Syp and PI3K binding motifs located in the C-terminus of the molecule were constructed. Human IRS-1 mutant constructs were generated to evaluate

how HAAH gene expression is upregulated by activation of the IRS-1 growth factor signal transduction cascade. Specific mutations in the C terminus of the hIRS-1 molecule abolished the various domains which bind to SH2-effector proteins such as Grb2, Syp and PI3K. The human IRS-1 protein contains the same Grb2 and Syp binding motifs of

5 897YVNI (underlined in Table 5, below and 1180YIDL (underlined in Table 5, below), respectively, as the rat IRS-1 protein. Mutants of hIRS-1 were constructed by substitution of a TAT codon (tyrosine) with a TTT codon (phenylalanine), in these motifs by use of oligonucleotide-directed mutagenesis using the following primers:

(5'-GGGGGAATTTGTCAATA-3' (SEQ ID NO:8) and 5'-GAATTTGTTAATATTG-3'

10 (SEQ ID NO:9), respectively). The cDNAs of hIRS-1 (wild-type) and mutants (tyrosine 897-to-phenylalanine and tyrosine 1180-to-phenylalanine) were subcloned into the pBK-CMV expression vector and designated as hIRS-1-wt, 897F, Δ Grb2), 1180F, and Δ Syp.

Table 6: Human IRS-1 amino acid sequence

	MASPPESDGF	SDVRKVGYL	KPKSMHKRFF	VLRAASEAGG	PARLEYEENE	KKWRHKSSAP	61
	KRSIPLESCF	NINKRADSKN	KHLVALYTRD	EHFAIAADSE	AEQDSWYQAL	LQLHNRKAGH	121
5	HDGAAALGAG	GGGGSCSGSS	GLGEAGEDLS	YGDVPPGPAF	KEVWQVILKP	KGLGQTKNLI	181
	GIYRLCLTSK	TISFVKLNSE	AAAVVLQLMN	IRRCGHSENF	FFIEVGRSAV	TGPGEFWMQV	241
	DDSVVAQNMH	ETILEAMRAM	SDEFPRRSKS	QSSSNCSNPI	SVPLRRHHLN	NPPPSQVGLT	301
	RRSRTESITA	TSPASMVGK	PGSFRVRASS	DGEGTMSRPA	SVDGSPVSPS	TNRTHAHRHR	361
	GSARLHPPLN	HSRSIPMPAS	RCSPSATSPV	SLSSSSSTSGH	GSTSDCLFPR	RSSASVSGSP	421
10	SDGGFISSDE	YGSSPCDFRS	SFRSVTPDSL	GHTPPARGEE	ELSNYICMGG	KGPSTLTAPN	481
	GHIILSRGGN	GHRCTPGTGL	GTSPALAGDE	AASAADLDNR	FRKRTHSAGT	SPTITHQKTP	541
	SOSSVASIEE	YTEMMPAYPP	GGSGGRLPG	HRHSFAFVPT	SYPEEGLEMH	PLERRGGHHR	601
	PDSSTLHTDD	GYMPMSPGVA	PVPSGRKGS	DYMPMSPKSV	SAPQIINPI	RRHPQRVDPN	661
	GYMMSPSGG	CSPDIGGGS	SSSSSSNAV	SGTSYGLWT	NGVGGHSHV	LPHPKPPVES	721
15	SGGKLLPCTG	DYMNMPVGD	SNTSSPDCY	YGPEDPQHKP	VLSYSLPRS	FKHTQRPGE	781
	EEGARHQHLR	LSTSSGRLLY	AATADSSSS	TSSDSLGGY	CGARLEPSLP	HPHHQVLQPH	841
	LPRKVDTAAG	TNSRLARPTR	LSLGDPAKST	LPRAREQQQ	QQPLHPPPEP	KSPGEYVNI	901
	FGSDQSGYLS	GPVAFHSSPS	VRCPSQLQPA	PREEETGTEE	YMKMDLGPGR	RAAWQESTGV	961
	EMGRIGPAPP	GAASICRPT	AVPSSRGDYM	TMQMSCPRQS	YVDTSPAAPV	SYADMRTGIA	1021
20	AEEVSLPRAT	MAAASSSSAA	SASPTGPQGA	AELAAHSSLL	GGPQGGGMS	AFTRVNLSPN	1081
	RNQSAKVIRA	DPQGCRRHS	SETFSSTPSA	TRVGNTVPFG	AGAAVGGGGG	SSSSSEDVCR	1141
	HSSASFENVW	LPRGELGGAP	KEPAKLCGAA	GGLLEGLNYI	DLDLVKDFKQ	CPQECTPEPQ	1201
	PPPPPPHPQ	LGSGESSSTR	RSEDL SAYA	SISFQKQPED	RQ (SEQ ID NO:5; GENBANK		
	Accession No. JS0670; pleckstrin domain spans residues 11-113, inclusive; Phosphate-binding residues include 46, 465, 551, 612, 632, 662, 732, 941, 989, or 1012 of SEQ ID NO:5)						
25							

Table 7: Human IRS-1 cDNA

30	cgccggcgccg	gtcggagggg	gccggcgccg	agagccagac	gccgccgctt	gttttggttg	61
	gggctctcgg	caactctccg	aggaggagga	ggaggaggga	ggaggggaga	agtaactgca	121
	gcggcagcgc	cctcccagag	aacaggcgct	ttccccgaac	cctccccaaa	cctcccccat	181
	ccccctctcg	ccttgtcccc	tccccctctc	cccagccgcc	tggagcgagg	ggcagggatg	241
	agtctgtccc	tccggccggt	ccccagctgc	agtggctgcc	cggatctcgt	tcgcatggaa	301
35	aagccacttt	ctccacccgc	cgagatgggc	ccggatgggg	ctgcagagga	cgcgcccgcg	361
	ggcgggcgga	gcagcagcag	cagcagcagc	agcaacagca	acagccgcag	cgccgcggtc	421
	tctgcgactg	agctggtatt	tgggcggctg	gtggcggtcg	ggacgggtgg	gggggtgggag	481
	gaggcgaagg	aggaggggaga	accccgtgca	acgttggggac	ttggcaaccc	gcctccccct	541
	gcccgaagat	atttaatttg	cctcggaat	cgctgcttcc	agaggggaac	tcaggaggga	601
40	aggcgcgcg	gcgcgcgcgc	tcctggaggg	gcaccgcagg	gacccccgac	tgctgcctcc	661
	ctgtgccgga	ctccagccgg	ggcgacgaga	gatgcatctt	cgctccttcc	tggtggcgcc	721
	ggcggtctag	aggagacttg	gctctcggag	gatcggggct	gccctcacc	cgagcgact	781
	gcctccccgc	cggcggtgag	cgcccgaaaa	ctccggtcgg	gctctctcct	gggctcagca	841
	gctgcgtcct	ccttcagctg	ccccctcccc	gcgcgggggg	cggcggtggat	ttcagagtcg	901
45	gggtttctgc	tgccctccagc	cctgttttga	tgtgccgggc	cgcggcgagg	agcctccgcc	961
	ccccaccggg	ttgtttttcg	gagcctccct	ctgctcagcg	ttggtggtgg	cgggtggcagc	1021
	atggcgagcc	ctccggagag	cgatggcttc	tcggacgtgc	gcaaggtggg	ctacctgcgc	1081
	aaacccaaga	gcatgcacaa	acgcttcttc	gtactgcgcg	cggccagcga	ggctgggggc	1141
	ccggcgcgcc	tcgagtacta	cgagaacgag	aagaagtggc	ggcacaagtc	gagcgccccc	1201
50	aaacgctcga	ttcccccttg	gagctgcttc	aacatcaaca	agcgggctga	ctccaagaac	1261
	aagcacctgg	tggtctctcta	cacccgggac	gagcactttg	ccatcgcggc	ggacagcgag	1321

	gccgagcaag	acagctggt	ccaggtctct	ctacagctgc	acaaccgtgc	taagggccac	1381
	cacgacggag	ctgcgccct	cggggcgga	ggtggtggg	gcagctgcag	cggcagctcc	1441
	ggccttggtg	aggctggga	ggacttgagc	tacggtgacg	tgeccccagg	acccgcatte	1501
	aaagaggtct	ggcaagtgat	cctgaagccc	aagggcctgg	gtcagacaaa	gaacctgatt	1561
5	ggtatctacc	gcctttgcct	gaccagcaag	accatcagct	tcgtgaagct	gaactcggag	1621
	gcagcggccg	tgggtgctgca	gctgatgaac	atcaggcgct	gtggccactc	ggaaaacttc	1681
	ttcttcatcg	aggtgggccc	ttctgcccgt	acggggcccg	gggagttctg	gatgcagggtg	1741
	gatgactctg	tgggtggcca	gaacatgcac	gagaccatcc	tggaggccat	gcggggccatg	1801
	agtgatgagt	tccgcccctg	cagcaagagc	cagtccctgt	ccaactgctc	taacccccatc	1861
10	agcgtccccc	tgcgcccgca	ccatctcaac	aatcccccg	ccagccaggt	ggggctgacc	1921
	cgccgatcac	gcactgagag	catcaccgcc	acctccccgg	ccagcatggg	gggagggaag	1981
	ccaggtctct	tccgtgtccg	cgctccaggt	gacggcgaa	gcaccatgtc	ccggccagcc	2041
	tcggtggagc	gcagccctgt	gagteccagc	accaacagaa	cccacgccc	ccggcatcgg	2101
	ggcagcgccc	ggctgcaccc	cccgtcaaac	cacagccgct	ccatcccat	gcccgtcttc	2161
15	cgtgtctcgc	cttcggccac	cagcccgggtc	agtctgtcgt	ccagtagcac	cagtggccat	2221
	ggctccacct	cggattgtct	cttcccacgg	cgtctagtgt	cttgggtgtc	tgggttcccc	2281
	agcgtatggc	gtttcatctc	ctcggatgag	tatggctcca	gtccctgcca	tttccggagt	2341
	tccttccgca	gtgtcactcc	ggattccctg	ggccacaccc	caccagccc	cgggtgaggag	2401
	gagctaagca	actatatctg	catgggtggc	aaggggccc	ccaccctgac	cgcccccaac	2461
20	ggtcactaca	ttttgtctcg	gggtggcaat	ggccaccgct	gcaccccagg	aacaggcttg	2521
	ggcacgagtc	cagccttggtc	tggggatgaa	gcagccagtg	ctgcagatct	ggataatcgg	2581
	ttccgaaaga	gaactcactc	ggcaggcaca	tccccacca	ttaccacca	gaagacccc	2641
	tccagtcct	cattgggttc	tacacagaga	tacacagaga	tgatgcctgc	ctaccacca	2701
	ggaggtggca	gtggaggccg	actgccggga	cacaggcact	ccgccttcgt	gcccacccgc	2761
25	tcctacccag	aggagggtct	ggaaatgcac	cccttggagc	gtcggggggg	gcaccaaccgc	2821
	ccagacagct	ccaccctcca	cacggatgat	ggctacatgc	ccatgtcccc	aggggtggcc	2881
	ccagtgcaca	gtggccgaaa	gggcagtgga	gactatatgc	ccatgagccc	caagagcgta	2941
	tctgccccac	agcagatcat	caatcccatc	agacgccatc	cccagagagt	ggaccccaat	3001
	ggctacatga	tgatgtcccc	cagcgggtggc	tgctctcctg	acattggagg	tggccccagc	3061
30	agcagcagca	gcagcagcaa	cgccgtccct	tccgggacca	gctatggaaa	gctgtggaca	3121
	aacggggtag	ggggccacca	ctctcatgtc	ttgctcacc	ccaaaccccc	agtggaggagc	3181
	agcgtgggta	agctcttacc	ttgcacaggt	gactatatga	acatgtcacc	agtgggggac	3241
	tccaacacca	gcagccccctc	cgactgctac	tacggccctg	aggaccccc	gcacaagcca	3301
	gtcctctcct	actactcatt	gccaaagatcc	tttaagcaca	cccagcgcgc	cggggagccg	3361
35	gaggagggtg	cccggcatca	gcacctccgc	ctttccacta	gctctggctg	ccttctctat	3421
	gctgcaacag	cagatgattc	ttcctcttcc	accagcagcg	acagcctggg	tgggggatac	3481
	tgcggggcta	ggctggagcc	cagccttcca	catccccacc	atcaggttct	gcagcccat	3541
	ctgcctcgaa	aggtggacac	agctgctcag	accaatagcc	gcctggccc	gcccacgagg	3601
	ctgtccctgg	gggatcccaa	ggccagcacc	ttacctcggg	cccagagagca	gcagcagcag	3661
40	cagcagccct	tgtctgaccc	tccagagccc	aagagcccgg	gggaatatgt	caatatgaa	3721
	tttgggagtg	atcagtctgg	ctacttgtct	ggcccgggtg	ctttccacag	ctcaccttct	3781
	gtcaggtgtc	catcccagct	ccagccagct	cccagagagg	aagagactgg	cactgaggag	3841
	tacatgaaga	tggacctggg	gcccggccgg	agggcagcct	ggcaggagag	cactgggggtc	3901
	gagatgggca	gactgggccc	tgcacctccc	ggggctgcta	gcatttgtag	gcctacccgg	3961
45	gcagtgcaca	gcagccgggg	tgactacatg	accatgcaga	tgagttgtcc	ccgtcagagc	4021
	tacgtggaca	cctcgccagc	tgcccctgta	agctatgctg	acatgcgaac	aggcattgct	4081
	gcagaggagg	tgagcctgct	cagggccacc	atggctgctg	cctcctcatc	ctcagcagcc	4141
	tctgtctccc	cgactgggccc	tcaaggggca	gcagagctgg	ctgcccactc	gtccctgctg	4201
	ggggggccac	aaggacctgg	gggcatgagc	gccttcaccc	gggtgaacct	cagtcctaac	4261
50	cgcaaccaga	gtgccaaagt	gatccgtgca	gaccacaag	ggtgccggcg	gaggcatagc	4321
	tccgagactt	tctcctcaac	acccagtgcc	acccgggtgg	gcaacacagt	gccctttgga	4381
	gcgggggcag	cagtaggggg	cggtggcggt	agcagcagca	gcagcgagga	tgtgaaacgc	4441
	cacagctctg	cttcccttga	gaatgtgtgg	ctgaggcctg	gggagcttgg	gggagccccc	4501
	aaggagccag	ccaaactgtg	tggggctgct	gggggtttgg	agaaatggct	taactacata	4561
55	gacctggatt	tgggtcaagga	cttcaaacag	tgccctcagg	agtgcacccc	tgaaccgcag	4621
	cctcccccc	ccccaccccc	tcatcaaccc	ctgggcagcg	gtgagagcag	ctccacccgc	4681

```

cgetcaagtg aggatttaag cgcctatgcc agcatcagtt tccagaagca gccagaggac 4741
cgtcagtagc tcaactggac atcacagcag aatgaagacc taaatgacct cagcaaatec 4801
tcttctaact catgggtacc cagactctaa atatttcag attcacaact aggacctcat 4861
atcttctca tcagtagatg gtaegatgca tccatttcag ttgttttaet ttatccaate 4921
5 ctcaggattt cattgactga actgcacgtt ctatattgtg ccaagcgaaa aaaaaaaatg 4981
cactgtgaca ccagaataat gagtctgcat aaacttcac ttcaacctta aggacttagc 5041
tggtccacagt gagctgatgt gccaccacc gtgtcatgag agaattgggt tactctcaat 5101
gcattttcaa gatacatttc atctgctgct gaaactgtgt acgacaaagc atcattgtaa 5161
attatttcat acaaaactgt tcacgttggg tggagagagt attaaatatt taacataggt 5221
10 tttgatttat atgtgtaatt ttttaaatga aaatgtaact tttcttacag cacatctttt 5281
ttttggatgt gggatggagg tatacaatgt tctgtgttaa agagtggagc aaatgcttaa 5341
aacaaggctt aaaagagtag aatagggtat gatccttgtt ttaagattgt aattcagaaa 5401
acataatata agaataatag tgccatagat ggttctcaat tgtatagtta tatttgctga 5461
tactatctct tgtcatataa acctgatgtt gagctgagtt cttataaga attaatctta 5521
15 attttgattt ttttctgta agacaatagg ccatgttaat taaactgaag aaggatatat 5581
ttggctgggt gttttcaaat gtcagcttaa aattggtaat tgaatggaag caaaattata 5641
agaagaggaa attaaagtct tccattgcat gtattgtaaa cagaaggaga tgggtgatte 5701
cttcaattca aaagctctct ttggaatgaa caatgtgggc gtttgtaaat tctggaaatg 5761
tctttctatt cataataaac tagatactgt tgatctttta aaaaaaaaaa 5821
20 aaaaaaaaa (SEQ ID NO:6; GENBANK Accession No. NM 005544)

```

The double mutation of tyrosine 897 and 1180 was constructed by replacement of 3'-sequences coding 897F by the same region of 1180F using restriction enzymes *NheI* and *EcoRI*, and this construct was called 897F1180F or Δ Grb2 Δ Syp. The expression plasmids were under control of a CMV promoter (hIRS-1-wt, Δ Grb2, Δ Syp, Δ Grb2, Δ Syp and pBK-CMV (mock) and linearized at the 3'-end of poly A signal sequences by *MluI* restriction enzymes followed by purification. A similar approach was used to change the tyrosine residue to phenylalanine at positions 613 and 942 to create the double PI3K mutant construct (Δ PI3K). The hIRS-1 mutants have a FLAG epitope (DYKDDDDK (SEQ ID NO:6) + stop codon) added to the C-terminus by PCR. This strategy allows to distinguish the mutant protein from "wild type" hIRS-1 in stable transfected cell lines. The mutants are used to define the link between the IRS signal transduction pathway and activation of HAAH as a downstream effector gene and identify compounds to inhibit transduction along the pathway to inhibit growth of tumors characterized by HAAH overexpression. Antibodies or other compounds which bind to phosphorylation sites or inhibit phosphorylation at those sites are used to inhibit signal transduction and thus proliferation of HAA-overexpressing tumors.

Other embodiments are within the following claims.

What is claimed is:

1. A method for diagnosing a malignant neoplasm in a mammal, comprising contacting a bodily fluid from said mammal with an antibody which binds to an human aspartyl (asparaginy) beta-hydroxylase (HAAH) polypeptide under conditions sufficient to form an antigen-antibody complex and detecting the antigen-antibody complex.
2. The method of claim 1, wherein said neoplasm is derived from endodermal tissue.
3. The method of claim 1, wherein said neoplasm is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.
4. The method of claim 1, wherein said neoplasm is a cancer of the central nervous system (CNS).
5. The method of claim 1, wherein said bodily fluid is selected from the group consisting of a CNS-derived bodily fluid, blood, serum, urine, saliva, sputum, lung effusion, and ascites fluid.
6. The method of claim 1, wherein said antibody is a monoclonal antibody.
7. The method of claim 6, wherein said monoclonal antibody is FB50.
8. The method of claim 6, wherein said monoclonal antibody is selected from the group consisting of 5C7, 5E9, 19B, 48A, 74A, 78A, 86A.
9. A method for prognosis of a malignant neoplasm of a mammal, comprising
 - (a) contacting a bodily fluid from said mammal with an antibody which binds to an HAAH polypeptide under conditions sufficient to form an antigen-antibody complex and detecting the antigen-antibody complex;
 - (b) quantitating the amount of complex to determine the level of HAAH in said fluid; and
 - (c) comparing the level of HAAH in said fluid with a normal control level of HAAH, wherein increasing levels of HAAH over time indicates an adverse prognosis.

10. A method of inhibiting tumor growth in a mammal comprising administering to said mammal a compound which inhibits expression of HAAH.
11. The method of claim 10, wherein said compound is a HAAH antisense nucleic acid.
12. The method of claim 11, wherein said HAAH antisense nucleic acid is 10-50 nucleotides in length.
13. The method of claim 10, wherein said the sequence of said HAAH antisense nucleic acid is complementary to a nucleic acid sequence is the 5' untranslated region of a HAAH gene.
14. The method of claim 10, wherein the sequence of said HAAH antisense nucleic acid comprises 5'CAT TCT TAC GCT GGG CCA TT 3' (SEQ ID NO:10).
15. The method of claim 10, wherein the sequence of said HAAH antisense nucleic acid comprises 5' TTA CGC TGG GCC ATT GCA CG 3' (SEQ ID NO:11)
16. The method of claim 10, wherein the sequence of said HAAH antisense nucleic acid comprises 5' CTG GGC CAT TGC ACG GTC CG 3' (SEQ ID NO:12).
17. The method of claim 10, wherein said compound is a ribozyme.
18. The method of claim 10, wherein said tumor is derived from endodermal tissue.
19. The method of claim 10, wherein said tumor is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.
20. The method of claim 10, wherein said tumor is a CNS tumor.
21. An HAAH antisense nucleic acid, wherein said nucleic acid comprises a sequence which is complementary to a sequence of a HAAH gene.
22. An HAAH antisense nucleic acid, wherein said nucleic acid comprises a sequence which is complementary to a noncoding sequence of a HAAH gene.

23. An HAAH antisense nucleic acid, wherein said nucleic acid comprises a sequence which is complementary to a sequence in the 5' untranslated region of a HAAH gene.
24. The nucleic acid of claim 23, wherein the sequence of said HAAH antisense nucleic acid comprises 5'CAT TCT TAC GCT GGG CCA TT 3' (SEQ ID NO:10).
25. The nucleic acid of claim,23, wherein the sequence of said HAAH antisense nucleic acid comprises 5' TTA CGC TGG GCC ATT GCA CG 3' (SEQ ID NO:11)
26. The nucleic acid of claim,23, wherein the sequence of said HAAH antisense nucleic acid comprises 5' CTG GGC CAT TGC ACG GTC CG 3' (SEQ ID NO:12).
27. A method of inhibiting tumor growth in a mammal comprising administering to said mammal a compound which inhibits an enzymatic activity of HAAH.
28. The method of claim 27, wherein said enzymatic activity is hydroxylase activity.
29. The method of claim 27, wherein said compound is a dominant negative mutant of HAAH.
30. The method of claim 29, wherein said dominant negative mutant HAAH comprises a mutation in a catalytic domain of HAAH.
31. The method of claim 27, wherein said compound is an HAAH-specific intrabody.
32. The method of claim 27, wherein said compound is L-mimosine.
33. The method of claim 27, wherein said compound is a hydroxypyridone.
34. A method of inhibiting tumor growth in a mammal comprising administering to said mammal a compound which inhibits signal transduction through the

IRS signal transduction pathway.

35. The method of claim 34, wherein said compound inhibits IRS phosphorylation.

36. The method of claim 34, wherein said compound inhibits binding of Fos or Jun to an HAAH promoter sequence.

37. A method of inhibiting tumor growth in a mammal comprising administering to said mammal a compound which inhibits HAAH hydroxylation of a NOTCH polypeptide.

38. The method of claim 37, wherein said compound inhibits hydroxylation of an EGF-like repeat sequence in a NOTCH polypeptide.

39. A method of killing a tumor cell comprising contacting said tumor cell with cytotoxic agent linked to an HAAH-specific antibody.

40. A monoclonal antibody that binds to an epitope of HAAH.

41. The antibody of claim 40, wherein said epitope is within a catalytic site of HAAH.

42. The antibody of claim 40, wherein said monoclonal antibody is selected from the group consisting of 5C7, 5E9, 19B, 48A, 74A, 78A, 86A.

43. The antibody of claim 40, wherein said monoclonal antibody is selected from the group consisting of HA238A, HA221, HA239, HA241, HA329, or HA355.

44. A composition comprising a monoclonal antibody that binds to an epitope of HAAH linked to a cytotoxic agent, wherein said composition preferentially kills tumor cells compared to non-tumor cells.

45. A kit for diagnosis of a tumor in a mammal, comprising the antibody of claim 29.

46. The kit of claim 45, wherein said antibody is immobilized on a solid phase.

47. The kit of claim 45, wherein said solid phase is selected from a group consisting of an assay plate, an assay well, a nitrocellulose membrane, a bead, a dipstick, and a component of an elution column.

48. A method of determining whether a candidate compound inhibits HAAH enzymatic activity, comprising

- (a) providing a HAAH polypeptide;
- (b) providing a polypeptide comprising an EGF-like domain;
- (c) contacting said HAAH polypeptide or said NOTCH polypeptide with said candidate compound;
- (d) determining hydroxylation of said polypeptide of step (b), wherein a decrease in hydroxylation in the presence of said candidate compound compared to that in the absence of said compound indicates that said compound inhibits HAAH enzymatic activity.

49. A method of determining whether a candidate compound inhibits HAAH activation of NOTCH, comprising

- (a) providing a cell expressing HAAH;
- (b) contacting said cell with a candidate compound; and
- (c) measuring translocation of activated NOTCH to the nucleus of said cell, wherein a decrease in translocation in the presence of said compound compared to that in the absence of said compound indicates that said compound HAAH activation of NOTCH.

Fig. 1




Fig. 2




Fig. 3a





Fig. 3b




**Fig. 4**

Fig. 5a




Fig. 5b




Fig. 5c




Fig. 5d





Fig. 6




Fig. 7

1. Cell proliferation
2. Up-regulation of growth genes
3. Resistance to apoptosis
4. Increased Invasive Properties
5. Secondary Genetic Events

Fig. 8




Fig. 9




Fig. 10




Fig. 11




Fig. 12




Fig 13




Fig. 14 A




Fig. 14 B





Fig. 14 C



(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
17 May 2001 (17.05.2001)

PCT

(10) International Publication Number
WO 01/035102 A3(51) International Patent Classification⁷: G01N 33/574,
33/573, A61K 31/7088, 31/713, C12N 15/11, A61K
38/44, 31/44, 47/48, C07K 16/40, C12Q 1/26, A61P 35/00

(21) International Application Number: PCT/US00/30738

(22) International Filing Date:
8 November 2000 (08.11.2000)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
09/436,184¹ 8 November 1999 (08.11.1999) US(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 09/436,184 (CIP)
Filed on 8 November 1999 (08.11.1999)(71) Applicant (for all designated States except US): RHODE
ISLAND HOSPITAL, A LIFESPAN PARTNER
[US/US]; 593 Eddy Street, Providence, RI 02902 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WANDS, Jack, R.
[US/US]; 210 Varick Road, Waban, MA 02168 (US). DE
LA MONTE, Suzanne, M. [US/US]; 1040 High Hawk
Road, East Greenwich, RI 02818 (US). INCE, Nedim
[TR/US]; Apt. #7, 40 Grove Street, Boston, MA 02114
(US). CARLSON, Rolf, I. [US/US]; 19 Bradford Street,
Boston, MA 02118 (US).(74) Agent: BEATTIE, Ingrid, A.; Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo PC, One Financial Center, Boston, MA
02111 (US).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS



(57) Abstract: The invention features a method for diagnosing a malignant neoplasm in a mammal by contacting a bodily fluid from the mammal with an antibody which binds to an human aspartyl (asparaginy) beta-hydroxylase (HAAH) polypeptide and methods of treating malignant neoplasms by inhibiting HAAH. Methods of inhibiting tumor growth by contacting a tumor cell with an HAAH antisense nucleic acid are also included.

WO 01/035102 A3



patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:
12 September 2002

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/574 G01N33/573 A61K31/7088 A61K31/713 C12N15/11
 A61K38/44 A61K31/44 A61K47/48 C07K16/40 C12Q1/26
 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>LAVAISSIERE L ET AL: "Overexpression of human aspartyl (asparaginy)) beta - hydroxylase in hepatocellular carcinoma and cholangiocarcinoma." JOURNAL OF CLINICAL INVESTIGATION, (1996 SEP 15) 98 (6) 1313-23., XP001004623 the whole document</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	<p>1-3,5-9, 45-47</p>

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 June 2001

Date of mailing of the international search report

15 AUG. 2001

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Gundlach, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/30738

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>NISHIMAKI, HIDEHARU (1) ET AL: "Expression of aspartyl (asparaginy) / beta - hydroxylase in human gastric tissue." JIKEIKAI MEDICAL JOURNAL, (SEPT., 1999) VOL. 46, NO. 3, PP. 129-136., XP001004554 abstract page 130, line 9 - line 21 page 131, paragraph 4 -page 133 page 134, paragraph 2 -page 135</p>	1-3,5-9, 45-47
X	<p>NISHIMAKI, H. (1) ET AL: "Cellular overexpression of human asparaginy / aspartyl beta- hydroxylase (HAAH) in gastric and colon cancers." GASTROENTEROLOGY, (1997) VOL. 112, NO. 4 SUPPL., PP. A628. MEETING INFO.: DIGESTIVE DISEASE WEEK AND THE 97TH ANNUAL MEETING OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION WASHINGTON, D.C., USA MAY 11-14, 1997, XP001004543 abstract</p>	1-3,5-9, 45-47
X	<p>INCE, N. (1) ET AL: "Overexpression of HAAH (human aspartyl, asparaginy hydroxylase) in bile ducts is related to malignant transformation" HEPATOLOGY, (1997) VOL. 26, NO. 4 PART 2, PP. 362A. MEETING INFO.: 48TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES CHICAGO, ILLINOIS, USA NOVEMBER 7-11, 1997, XP001004629 abstract</p>	1-3,5-9, 45-47
X	<p>DE LA MONTE, S. M. ET AL: "Aspartyl (Asparaginy) beta hydroxylase (AAH) expression marks invasiveness of primary malignant CNS neoplasms." MODERN PATHOLOGY, (JAN., 1999) VOL. 12, NO. 1, PP. 170A. MEETING INFO.: ANNUAL MEETING OF THE UNITED STATES AND CANADIAN ACADEMY O PATHOLOGY SAN FRANCISCO, CALIFORNIA, USA MARCH 20-26, 1999, XP001004547 abstract</p>	1,2,4,5

-/--

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 00/30738

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	INCE N ET AL: "Overexpression of human aspartyl (asparaginy) beta - hydroxylase is associated with malignant transformation." CANCER RESEARCH, (2000 MAR 1) 60 (5) 1261-6., XP001002102 the whole document -----	1-3,5-9, 45-47

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/30738

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

see further information sheet invention group 1

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-9,45-47

Method for diagnosing malignant neoplasms with antibodies

2. Claims: 10-44

Method of inhibiting tumor growth in a mammal using a compound which inhibits the expression of HAAH

3. Claims: 48,49

Methods of determining whether candidate compounds inhibit HAAH

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:



BLACK BORDERS

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)